var title_f3_45_3792="Breast abscess with skin necrosis";
var content_f3_45_3792=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F60139&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F60139&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Breast abscess with skin necrosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 363px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    When the overlying skin is thinned or necrotic, the optimal&nbsp;procedure is excision of&nbsp;the necrotic skin, which allows the abscess to drain.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Michael J Dixon, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_45_3792=[""].join("\n");
var outline_f3_45_3792=null;
var title_f3_45_3793="Peripheral IV placement 5";
var content_f3_45_3793=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F70200&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F70200&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Peripheral IV placement: Advancing the catheter",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Once a flash of blood appears in the needle chamber, advance the needle another millimeter or two. Then use the index finger of your dominant hand to slide the catheter forward over the needle and into the vein.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Robert Frank, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_45_3793=[""].join("\n");
var outline_f3_45_3793=null;
var title_f3_45_3794="Patient information: Prenatal hydronephrosis (The Basics)";
var content_f3_45_3794=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/16335\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/27/14769\">",
"         Anatomy of the urinary tract in children",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?41/57/42897\">",
"         Patient information: Amniocentesis (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?38/46/39663\">",
"         Patient information: Chorionic villus sampling (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?27/25/28048\">",
"         Patient information: Kidney infection (pyelonephritis) (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Prenatal hydronephrosis (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/prenatal-hydronephrosis-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H2736742\">",
"      <span class=\"h1\">",
"       What is prenatal hydronephrosis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;&ldquo;Prenatal&rdquo; means that a condition happens during pregnancy, when a baby is in the mother&rsquo;s uterus (womb). Prenatal hydronephrosis is a condition that involves 1 or both of the baby&rsquo;s kidneys (",
"      <a class=\"graphic graphic_figure graphicRef65630 \" href=\"UTD.htm?14/27/14769\">",
"       figure 1",
"      </a>",
"      ). Kidneys work to make urine. Each kidney has 2 parts:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        A part that filters the blood and removes waste and excess salt and water",
"       </li>",
"       <li>",
"        A part that collects the urine",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      In hydronephrosis, the part of the kidney that collects the urine has too much urine in it. This causes it to swell and get bigger than normal.",
"     </p>",
"     <p>",
"      Some babies have hydronephrosis that lasts only for a short time and then goes away. This condition is not serious and doesn&rsquo;t cause any long-term problems.",
"     </p>",
"     <p>",
"      If the hydronephrosis doesn&rsquo;t go away, it could be caused by a serious problem in the urinary tract. For example, there might be a block in the urinary tract, or urine might flow backwards from the bladder to the kidney.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H2736749\">",
"      <span class=\"h1\">",
"       How do I know if my baby has prenatal hydronephrosis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Doctors find out a baby has it when they do a routine imaging test, called an ultrasound, to check on the baby during pregnancy. An ultrasound creates pictures of the baby inside the uterus. Prenatal hydronephrosis does not cause any symptoms.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H2736756\">",
"      <span class=\"h1\">",
"       Will I need more tests?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. If your baby has hydronephrosis, your doctor will want to see if it goes away or not, or gets worse. You will have 1 or more ultrasounds to follow up during your pregnancy.",
"     </p>",
"     <p>",
"      When your doctor does an ultrasound, he or she will check:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        If 1 or both kidneys have hydronephrosis",
"       </li>",
"       <li>",
"        How severe the condition is",
"       </li>",
"       <li>",
"        Your amniotic fluid &mdash; Amniotic fluid is the fluid in the uterus that surrounds the baby. It is made up of the baby&rsquo;s urine. If a problem keeps the kidneys from making enough urine, the amount of amniotic fluid will be low.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If the follow-up ultrasound shows that the hydronephrosis has gone away, you probably won&rsquo;t need any more tests.",
"     </p>",
"     <p>",
"      If the follow-up ultrasound shows that the hydronephrosis has not gone away or is worse, you will likely need more tests. These can include more ultrasounds or tests to look for other conditions.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H2736763\">",
"      <span class=\"h1\">",
"       How is prenatal hydronephrosis treated during pregnancy?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Doctors follow the condition with tests, but they do not usually treat it.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H2736770\">",
"      <span class=\"h1\">",
"       How is hydronephrosis treated after birth?",
"      </span>",
"      &nbsp;&mdash;&nbsp;It depends on the number of kidneys involved and how severe the condition was before birth.",
"     </p>",
"     <p>",
"      If the hydronephrosis went away before birth, your baby will not need any tests or treatment after birth.",
"     </p>",
"     <p>",
"      If the hydronephrosis did not go away, your baby will need tests after birth. He or she might also need treatment.",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        If the condition involved only 1 kidney or was mild, your baby will have an ultrasound after he or she is 1 week old. Depending on those results, he or she might need other tests. Your baby&rsquo;s doctor might also prescribe an antibiotic medicine. This medicine can help prevent your baby from getting a kidney infection.",
"       </li>",
"       <li>",
"        If the condition involved both kidneys or was severe, your baby will have an ultrasound within the first few days of life. Your baby&rsquo;s doctor will probably prescribe an antibiotic medicine. This medicine can help prevent your baby from getting a kidney infection. Your baby might also need other tests to check the urinary tract.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H2736777\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?41/57/42897?source=see_link\">",
"       Patient information: Amniocentesis (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?38/46/39663?source=see_link\">",
"       Patient information: Chorionic villus sampling (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?27/25/28048?source=see_link\">",
"       Patient information: Kidney infection (pyelonephritis) (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?3/45/3794?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16335 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-5CF79EDF2C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_45_3794=[""].join("\n");
var outline_f3_45_3794=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2736742\">",
"      What is prenatal hydronephrosis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2736749\">",
"      How do I know if my baby has prenatal hydronephrosis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2736756\">",
"      Will I need more tests?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2736763\">",
"      How is prenatal hydronephrosis treated during pregnancy?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2736770\">",
"      How is hydronephrosis treated after birth?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2736777\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/16335\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/27/14769\">",
"      Anatomy of the urinary tract in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?41/57/42897?source=related_link\">",
"      Patient information: Amniocentesis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?38/46/39663?source=related_link\">",
"      Patient information: Chorionic villus sampling (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?27/25/28048?source=related_link\">",
"      Patient information: Kidney infection (pyelonephritis) (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_45_3795="Patient information: Recovery after stroke (The Basics)";
var content_f3_45_3795=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?29/61/30674\">",
"         Patient information: Aphasia (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?12/14/12512\">",
"         Patient information: Carotid artery disease (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?26/23/26994\">",
"         Patient information: Dysarthria (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?21/34/22050\">",
"         Patient information: Hemorrhagic stroke (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?33/58/34722\">",
"         Patient information: High blood pressure in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?38/40/39554\">",
"         Patient information: Lowering the risk of having another stroke (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?35/37/36435\">",
"         Patient information: Medicines after an ischemic stroke (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?23/55/24435\">",
"         Patient information: Stroke (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?34/22/35170\">",
"         Patient information: Transient ischemic attack (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?7/63/8180\">",
"         Patient information: Hemorrhagic stroke treatment (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?18/53/19286\">",
"         Patient information: Ischemic stroke treatment (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?37/37/38484\">",
"         Patient information: Stroke symptoms and diagnosis (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Recovery after stroke (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/recovery-after-stroke-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H6591085\">",
"      <span class=\"h1\">",
"       What happens after a person has a stroke?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Strokes affect people in different ways. Some people who have a stroke have no lasting effects. Others lose important brain functions. For example, some people become partly paralyzed or unable to speak.",
"     </p>",
"     <p>",
"      Here are some of the most common long-term problems that can be caused by a stroke:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        <strong>",
"         Speech problems",
"        </strong>",
"        &ndash; People who have a stroke sometimes lose the ability to speak or understand speech. The medical term for this is &ldquo;aphasia.&rdquo; Some people might have only slurred speech. The medical term for this is &ldquo;dysarthria.&rdquo;",
"       </li>",
"       <li>",
"        <strong>",
"         Weakness and movement problems",
"        </strong>",
"        &ndash; People who have a stroke sometimes have muscle weakness or paralysis of the left or right side of the body. The muscle weakness can affect the face, arm, and leg. The medical term for this is &ldquo;hemiparesis.&rdquo; People who have a stroke can also have trouble walking, grasping objects, or balancing. Plus, they can lose the ability to make controlled, planned movements, even if the stroke did not cause weakness or loss of sensation. The medical term for being unable to make planned, controlled movements is &ldquo;apraxia.&rdquo;",
"       </li>",
"       <li>",
"        <strong>",
"         Partial loss of sensation",
"        </strong>",
"        &ndash; People who have stroke sometimes have partial or total loss of sensation on the left or right half of their body.",
"       </li>",
"       <li>",
"        <strong>",
"         Trouble eating or swallowing",
"        </strong>",
"        &ndash; People who have a stroke sometimes have trouble swallowing. The medical term for this is &ldquo;dysphagia.&rdquo; Sometimes this problem causes food to go down the wrong way and into the lungs. This can be dangerous because it can lead to lung infections, such as pneumonia. Some people need a feeding tube to deal with this problem.",
"       </li>",
"       <li>",
"        <strong>",
"         Problems thinking clearly or interacting with others",
"        </strong>",
"        &ndash; People who have stroke sometimes get confused easily or have trouble staying focused. They can also have personality changes that make them react differently to others. Sometimes they have mood swings for no apparent reason. They might be sad 1 moment and angry the next.",
"       </li>",
"       <li>",
"        <strong>",
"         Depression",
"        </strong>",
"        &ndash; People who have a stroke also sometimes get depressed. This can make recovery even harder. It&rsquo;s important to get treated for depression after a stroke.",
"       </li>",
"       <li>",
"        <strong>",
"         Problems with bladder control &ndash;",
"        </strong>",
"        People who have a stroke sometimes lose bladder control or leak urine. The medical term for this is &ldquo;urinary incontinence.&rdquo; It often gets better over time.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H6591102\">",
"      <span class=\"h1\">",
"       What happens during recovery from a stroke?",
"      </span>",
"      &nbsp;&mdash;&nbsp;During recovery, people work to regain some of the abilities they lost. Even though a part of their brain was damaged by the stroke, their brain can re-learn how to do some of the things it used to do.",
"     </p>",
"     <p>",
"      People who lose the ability to speak can often re-learn how to speak or at least how to communicate to some degree. In the same way, people who lose the ability to walk can sometimes re-learn how to walk. (Some people need to use canes or other devices to walk.)",
"     </p>",
"     <p>",
"      Often recovery involves treatment in a stroke &ldquo;rehabilitation&rdquo; facility, also called stroke &ldquo;rehab.&rdquo; In rehab, there are all kinds of medical professionals who specialize in helping people who have had a stroke. If you go to stroke rehab, the people there can:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Help you regain some of the abilities you lost",
"       </li>",
"       <li>",
"        Give you tips on how to cope with the problems caused by the stroke",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Here are just a few examples of how a rehab specialist could help you:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        If you can no longer walk very well,",
"        <strong>",
"         a physical therapist",
"        </strong>",
"        (exercise expert) can show you ways to improve the way you walk. He or she can also recommend braces, canes, and other devices that might make it easier for you to walk.",
"       </li>",
"       <li>",
"        If you can no longer swallow well,",
"        <strong>",
"         a speech and language therapist",
"        </strong>",
"        can teach you to do exercises that can improve how you swallow. He or she can also offer tips on how to cope with swallowing problems. For instance, the therapist might suggest you add powders or other ingredients to the liquids you drink, so that they are thick and less likely to go down the wrong way.",
"       </li>",
"       <li>",
"        If you can no longer hold your toothbrush to brush your teeth,",
"        <strong>",
"         an occupational therapist",
"        </strong>",
"        can show you new ways of holding your brush, so that you can use it.",
"       </li>",
"       <li>",
"        If you are depressed because you had a stroke,",
"        <strong>",
"         a psychiatrist",
"        </strong>",
"        (doctor who specializes in mental health) can prescribe medicines to treat depression. He or she can also talk to you about the way you feel about the stroke.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H6591117\">",
"      <span class=\"h1\">",
"       What are the chances of full recovery after a stroke?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The chances of making a full recovery depend on a lot of factors, such as:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        How big the stroke was",
"       </li>",
"       <li>",
"        What part of the brain was damaged by the stroke",
"       </li>",
"       <li>",
"        How old the person is (Younger people tend to recover better than older people.)",
"       </li>",
"       <li>",
"        What other medical problems the person has (such as heart failure or cancer)",
"       </li>",
"       <li>",
"        Whether the person was sick before the stroke happened",
"       </li>",
"       <li>",
"        How soon the person was treated following the stroke",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Scientists used to think that when a part of the brain was damaged, there was no way to recover what was lost. It turns out that is not true. The brain can recover some and adapt. The most important thing you can do to help make this happen is to stick with rehab and do all the exercises and therapies your healthcare team recommends. Also, be patient. It takes time to heal and learn new ways to cope, but work and patience can pay off.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H6591132\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?23/55/24435?source=see_link\">",
"       Patient information: Stroke (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?29/61/30674?source=see_link\">",
"       Patient information: Aphasia (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?26/23/26994?source=see_link\">",
"       Patient information: Dysarthria (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?38/40/39554?source=see_link\">",
"       Patient information: Lowering the risk of having another stroke (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?35/37/36435?source=see_link\">",
"       Patient information: Medicines after an ischemic stroke (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?21/34/22050?source=see_link\">",
"       Patient information: Hemorrhagic stroke (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?34/22/35170?source=see_link\">",
"       Patient information: Transient ischemic attack (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?12/14/12512?source=see_link\">",
"       Patient information: Carotid artery disease (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?33/58/34722?source=see_link\">",
"       Patient information: High blood pressure in adults (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?37/37/38484?source=see_link\">",
"       Patient information: Stroke symptoms and diagnosis (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?18/53/19286?source=see_link\">",
"       Patient information: Ischemic stroke treatment (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?7/63/8180?source=see_link\">",
"       Patient information: Hemorrhagic stroke treatment (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?3/45/3795?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16266 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-61.234.146.186-D9A34E86B4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_45_3795=[""].join("\n");
var outline_f3_45_3795=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6591085\">",
"      What happens after a person has a stroke?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6591102\">",
"      What happens during recovery from a stroke?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6591117\">",
"      What are the chances of full recovery after a stroke?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6591132\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?29/61/30674?source=related_link\">",
"      Patient information: Aphasia (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?12/14/12512?source=related_link\">",
"      Patient information: Carotid artery disease (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?26/23/26994?source=related_link\">",
"      Patient information: Dysarthria (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?21/34/22050?source=related_link\">",
"      Patient information: Hemorrhagic stroke (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?7/63/8180?source=related_link\">",
"      Patient information: Hemorrhagic stroke treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?33/58/34722?source=related_link\">",
"      Patient information: High blood pressure in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?18/53/19286?source=related_link\">",
"      Patient information: Ischemic stroke treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?38/40/39554?source=related_link\">",
"      Patient information: Lowering the risk of having another stroke (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/37/36435?source=related_link\">",
"      Patient information: Medicines after an ischemic stroke (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?23/55/24435?source=related_link\">",
"      Patient information: Stroke (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?37/37/38484?source=related_link\">",
"      Patient information: Stroke symptoms and diagnosis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?34/22/35170?source=related_link\">",
"      Patient information: Transient ischemic attack (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_45_3796="Nimodipine: Patient drug information";
var content_f3_45_3796=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Nimodipine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/20/16710?source=see_link\">",
"     see \"Nimodipine: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F201614\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Nimotop&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10013481\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700805",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not give this drug as a shot. Unsafe effects may happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10013483\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691314",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to calm the brain when there has been bleeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10013482\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702605",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to nimodipine or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10013487\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698416",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood pressure and heart rate checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696668",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid grapefruit and grapefruit juice.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697562",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Limit your drinking of wine, beer, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10013488\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10013490\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698655",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10013485\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695887",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take on an empty stomach. Take 1 hour before or 2 hours after meals.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10013486\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10013491\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10013492\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10909 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-122.72.80.101-1C61674EA5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_45_3796=[""].join("\n");
var outline_f3_45_3796=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201614\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013481\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013483\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013482\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013487\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013488\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013490\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013485\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013486\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013491\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013492\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?16/20/16710?source=related_link\">",
"      Nimodipine: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_45_3797="Hydroxyzine: Patient drug information";
var content_f3_45_3797=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Hydroxyzine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/24/391?source=see_link\">",
"     see \"Hydroxyzine: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/23/19830?source=see_link\">",
"     see \"Hydroxyzine: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F181115\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Vistaril&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F181116\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Hydroxyzine&reg;;",
"     </li>",
"     <li>",
"      Atarax&reg;;",
"     </li>",
"     <li>",
"      Hydroxyzine Hydrochloride Injection, USP;",
"     </li>",
"     <li>",
"      Novo-Hydroxyzin;",
"     </li>",
"     <li>",
"      Nu-Hydroxyzine;",
"     </li>",
"     <li>",
"      PMS-Hydroxyzine;",
"     </li>",
"     <li>",
"      Riva-Hydroxyzine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10017000\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691589",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to ease allergy signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691728",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat anxiety.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691985",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat upset stomach and throwing up.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10016999\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702276",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to hydroxyzine or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701055",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are less than 12 weeks pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10017004\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697173",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have asthma, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697225",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have glaucoma, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697349",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have trouble passing urine, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10017005\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10017007\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699104",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to pass urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699057",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Big change in balance.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699112",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10017002\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705490",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694319",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       There is a liquid (suspension, syrup) if you cannot swallow pills. Shake suspension well before use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696107",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Those who have feeding tubes may also use the liquid. Flush the feeding tube before and after this drug is given.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695985",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a muscle.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10017003\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705490",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is taken on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10017008\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705490",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699596",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10017009\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10748 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-203.80.222.8-5CA963D2D9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_45_3797=[""].join("\n");
var outline_f3_45_3797=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181115\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181116\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017000\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016999\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017004\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017005\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017007\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017002\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017003\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017008\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017009\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?0/24/391?source=related_link\">",
"      Hydroxyzine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/23/19830?source=related_link\">",
"      Hydroxyzine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_45_3798="Muscles of the lateral abdominal wall";
var content_f3_45_3798=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F66280&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F66280&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 552px\">",
"   <div class=\"ttl\">",
"    Muscles of the lateral abdominal wall",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 532px; height: 702px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_45_3798=[""].join("\n");
var outline_f3_45_3798=null;
var title_f3_45_3799="Evaluation of parasympathetic nervous system function";
var content_f3_45_3799=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Evaluation of parasympathetic nervous system function",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/45/3799/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/45/3799/contributors\">",
"     Roy Freeman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/45/3799/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/45/3799/contributors\">",
"     Jeremy M Shefner, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/45/3799/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/45/3799/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?3/45/3799/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 22, 2009.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The laboratory evaluation of the parasympathetic nervous system includes measures of heart rate variation at rest and in response to deep respiration, a Valsalva maneuver, postural changes, and apneic facial immersion. These tests primarily provide an index of vagal cardiac function [",
"    <a class=\"abstract\" href=\"UTD.htm?3/45/3799/abstract/1\">",
"     1",
"    </a>",
"    ]. The technical aspects of heart rate variability and its clinical applications are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/22/10601?source=see_link\">",
"     \"Heart rate variability: Use after myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/39/35449?source=see_link\">",
"     \"Heart rate variability: Uses other than after myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/10/4264?source=see_link\">",
"     \"Heart rate variability: Technical aspects\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     SHORT-TERM MEASURES OF HEART RATE VARIABILITY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Respiration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The beat to beat variability in heart rate accompanying respiration at normal respiratory rates is predominantly mediated by the vagus nerve and is reduced or abolished by vagotomy, vagus nerve cooling, and muscarinic blockade. The determinants of the respiratory fluctuations in heart rate include a stretch reflex from the lungs and thoracic wall, changes in cardiac filling, arterial baroreceptor responses to blood pressure changes, changes in baroreflex sensitivity with respiratory phase, and respiratory center activity overflow to medullary vasomotor neurons [",
"    <a class=\"abstract\" href=\"UTD.htm?3/45/3799/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite these multiple mechanisms that involve several reflex arcs, respiratory sinus arrhythmia has provided a valuable window for determining autonomic nervous system control of cardiovascular function and an important index of autonomic nervous system pathology. Use of the amplitude of the beat-to-beat variation with respiration as a clinical measure of autonomic nervous system function was first suggested in the 1970s [",
"    <a class=\"abstract\" href=\"UTD.htm?3/45/3799/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. In the ensuing years, additional measures have been proposed including the standard deviation of the R-R interval [",
"    <a class=\"abstract\" href=\"UTD.htm?3/45/3799/abstract/4\">",
"     4",
"    </a>",
"    ], the mean square successive difference [",
"    <a class=\"abstract\" href=\"UTD.htm?3/45/3799/abstract/5\">",
"     5",
"    </a>",
"    ], the mean successive difference [",
"    <a class=\"abstract\" href=\"UTD.htm?3/45/3799/abstract/4\">",
"     4",
"    </a>",
"    ], the expiratory-inspiratory ratio (E:I ratio) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/45/3799/abstract/3\">",
"     3",
"    </a>",
"    ], and the mean circular resultant [",
"    <a class=\"abstract\" href=\"UTD.htm?3/45/3799/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. Although the mean circular resultant has not attained widespread use, it was the sole test of heart rate variability with respiration used to assess parasympathetic function in the Diabetes Control and Complications Trial [",
"    <a class=\"abstract\" href=\"UTD.htm?3/45/3799/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The laboratory or bedside tests of heart rate variability with deep breathing are usually performed in the supine position where vagal tone is greatest. However, some authors have advocated the seated position. Typically, the test is performed over six respiratory cycles with a respiratory rate of six breaths per minute, although other paradigms are also used [",
"    <a class=\"abstract\" href=\"UTD.htm?3/45/3799/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The amplitude of the beat-to-beat variation with respiration (ie, the maximum minus minimum heart rate difference measured in beats per minute) and the E:I ratio are generally regarded as the simplest and most reliable measures of heart rate variability in response to deep respiration. The maximum heart rate variation in response to deep breathing is a sensitive and specific index of autonomic function. This test is the best noninvasive test to assess cardiac vagal innervation.",
"   </p>",
"   <p>",
"    The standard deviation of the R-R interval or instantaneous heart rate is the most widely used statistical measure of heart rate variability. This measure is more frequently used to assess heart rate variability over longer periods (five minutes to 24 hours), although it can be used to assess heart rate variability in the smaller segments more typically obtained during clinical testing. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/10/4264?source=see_link\">",
"     \"Heart rate variability: Technical aspects\"",
"    </a>",
"    .) Other commonly used statistical approaches are based upon the hypothesis that successive differences in the R-R intervals, ie, the actual differences between adjacent R-R intervals, would be more sensitive than the standard deviation to short-term fluctuations in heart rate. The mean square successive difference (MSSD) is the average of the square of the differences between successive beats [",
"    <a class=\"abstract\" href=\"UTD.htm?3/45/3799/abstract/5\">",
"     5",
"    </a>",
"    ], the rMSSD is its square root [",
"    <a class=\"abstract\" href=\"UTD.htm?3/45/3799/abstract/9\">",
"     9",
"    </a>",
"    ], the mean successive difference (MSD) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/45/3799/abstract/4\">",
"     4",
"    </a>",
"    ] is the average of the differences between successive beats, while the SDSD is the standard deviation of the successive differences [",
"    <a class=\"abstract\" href=\"UTD.htm?3/45/3799/abstract/10\">",
"     10",
"    </a>",
"    ]. Unlike the standard deviation, these measures are dependent upon the sequence of RR intervals.",
"   </p>",
"   <p>",
"    The measurements are theoretically robust against gradual trends in heart rate over time and are independent of mean heart rate in most [",
"    <a class=\"abstract\" href=\"UTD.htm?3/45/3799/abstract/11\">",
"     11",
"    </a>",
"    ] but not all studies [",
"    <a class=\"abstract\" href=\"UTD.htm?3/45/3799/abstract/12\">",
"     12",
"    </a>",
"    ]. They are, however, sensitive to ectopic beats such as ventricular premature beats, ie, a short interval followed by a long compensatory pause [",
"    <a class=\"abstract\" href=\"UTD.htm?3/45/3799/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are a number of factors that influence respiratory mediated heart rate variability. Respiratory sinus arrhythmia is dependent on the both the frequency and depth of respiration; that is, the magnitude of change in heart rate at a given respiratory rate is dependent on the tidal volume and, for a specific tidal volume, the magnitude of heart rate variability is dependent on the breathing frequency. Several time and frequency domain studies have suggested that the amplitude of the heart rate increase is maximal at respiratory rates between 5 to 10 breaths per minute [",
"    <a class=\"abstract\" href=\"UTD.htm?3/45/3799/abstract/13\">",
"     13",
"    </a>",
"    ]. Smaller changes in heart rate occur at lower and higher respiratory rates for a given tidal volume [",
"    <a class=\"abstract\" href=\"UTD.htm?3/45/3799/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. The maximal heart rate response in subjects with an autonomic neuropathy occurs at lower respiratory rates [",
"    <a class=\"abstract\" href=\"UTD.htm?3/45/3799/abstract/13,16\">",
"     13,16",
"    </a>",
"    ]. Other potential confounders that may reduce respiratory mediated heart rate variability include hypocapnia (that may occur with hyperventilation) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/45/3799/abstract/17\">",
"     17",
"    </a>",
"    ] and increased sympathetic outflow [",
"    <a class=\"abstract\" href=\"UTD.htm?3/45/3799/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is a well established relationship between age and heart rate variability. This relationship has been expressed in most studies as a linear decline in the heart rate response to deep breathing with increasing age [",
"    <a class=\"abstract\" href=\"UTD.htm?3/45/3799/abstract/19\">",
"     19",
"    </a>",
"    ]. These studies suggest a decline in heart rate variability of 3 to 5 beats per minute per decade in control subjects.",
"   </p>",
"   <p>",
"    The diagnostic discrimination of this test is reduced by the use of a single normal value for all ages, which may lead to false-negative test results in younger patients and false-positive results in older patients. As examples of the age-related decline in the maximum minus minimum heart rate difference with deep respiration, the fifth percentile cut off is as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      14 beats per minute (bpm) in 10 to 29-year-old males and females",
"     </li>",
"     <li>",
"      12 bpm in 30 to 39-year-olds",
"     </li>",
"     <li>",
"      10 bpm in 40 to 49-year-olds",
"     </li>",
"     <li>",
"      9 bpm in 50 to 59-year-olds",
"     </li>",
"     <li>",
"      7 bpm in 60 to 79-year-olds [",
"      <a class=\"abstract\" href=\"UTD.htm?3/45/3799/abstract/19\">",
"       19",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Valsalva maneuver",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Valsalva maneuver provides a measure of sympathetic, vagal, and baroreceptor function. The maneuver is typically performed by blowing through a mouthpiece connected to a mercury manometer for 15 or 20 seconds. The mercury column of the manometer is maintained at 40 mmHg. There should be a small air leak in the system to prevent closing of the glottis. An expiratory pressure of 40 mmHg appears to result in an optimal response; lower levels do not provide an adequate stimulus, while higher levels result in poor reproducibility. This test should be repeated several times to ensure a reproducible response [",
"    <a class=\"abstract\" href=\"UTD.htm?3/45/3799/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The normal Valsalva maneuver has four phases:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Phase 1 consists of a transient rise in arterial pressure and an associated decrease in heart rate",
"     </li>",
"     <li>",
"      Phase 2, during the expiratory phase of the maneuver, is characterized by a gradual fall in blood pressure followed by a recovery; an increase in heart rate accompanies this phase",
"     </li>",
"     <li>",
"      Phase 3 consists of a sudden brief fall in blood pressure with an accompanying increase in heart rate occurring with the cessation of straining.",
"     </li>",
"     <li>",
"      Phase 4 is characterized by an increase in blood pressure above the resting value (the \"overshoot\") and by bradycardia.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Phases 1 and 3 most likely reflect mechanical factors, while phases 2 and 4 are a consequence of sympathetic, vagal, and baroreflex interactions [",
"    <a class=\"abstract\" href=\"UTD.htm?3/45/3799/abstract/21-25\">",
"     21-25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The heart rate change in response to this maneuver is a widely used indirect, sensitive, specific, and reproducible measure of autonomic function. The Valsalva ratio, the ratio of the shortest RR interval (the tachycardia) during or after phase II of the maneuver to the longest RR interval (the bradycardia) in phase IV of the maneuver, is the most commonly used measure derived from the maneuver. Other statistical measures of the heart rate response to the maneuver include the tachycardia ratio, the ratio of the shortest RR interval during the maneuver to the longest RR interval before the maneuver, which may be more reproducible but more dependent on resting heart rate than the Valsalva ratio [",
"    <a class=\"abstract\" href=\"UTD.htm?3/45/3799/abstract/22,23,26,27\">",
"     22,23,26,27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Variables that influence the Valsalva ratio include age [",
"    <a class=\"abstract\" href=\"UTD.htm?3/45/3799/abstract/28\">",
"     28",
"    </a>",
"    ] and the duration and magnitude of expiratory effort [",
"    <a class=\"abstract\" href=\"UTD.htm?3/45/3799/abstract/20\">",
"     20",
"    </a>",
"    ]. In addition, when sympathetic outflow is deficient, parasympathetic activity cannot be adequately assessed because blood pressure during phase IV does not increase and there is therefore no stimulus to increase vagal activity [",
"    <a class=\"abstract\" href=\"UTD.htm?3/45/3799/abstract/29\">",
"     29",
"    </a>",
"    ]. When these variables are properly controlled, the heart rate response to the Valsalva maneuver is a sensitive and specific test of cardiac vagal innervation.",
"   </p>",
"   <p>",
"    Age and gender-based norms should be used for the Valsalva ratio. As an example, the fifth percentile Valsalva ratio cut-off point is as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?3/45/3799/abstract/19\">",
"     19",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      1.59 for males and 1.46 for females ages 10 to 29",
"     </li>",
"     <li>",
"      1.52 for males and 1.50 for females ages 30 to 39",
"     </li>",
"     <li>",
"      1.44 for males and 1.51 for females ages 40 to 49",
"     </li>",
"     <li>",
"      1.36 for males and 1.47 for females ages 50 to 59",
"     </li>",
"     <li>",
"      1.29 for males and 1.39 for females ages 60 to 69",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Assumption of upright posture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Moving from the supine to upright posture results in the translocation of 300 to 800 cc of blood from the central intravascular compartment to dependent regions in the legs, buttocks, pelvis, and splanchnic circulation. This orthostatic stress evokes a sequence of compensatory cardiovascular responses to maintain homeostasis.",
"   </p>",
"   <p>",
"    Analysis of the heart rate response to the upright posture provides a measure of the sympathetic nervous system, the parasympathetic nervous system, and baroreceptor function. Active standing results in an abrupt increase in heart rate that peaks at approximately 3 seconds followed by a more gradual increase that peaks at approximately 12 seconds.",
"   </p>",
"   <p>",
"    The initial increase in heart rate is mediated by sudden inhibition of vagal tone, while the more gradual increase is due to further vagal inhibition and sympathetic activation. The initial heart rate increase is most likely an \"exercise reflex\" evoked by the integration of afferent signals from contracting muscle with signals from higher brain centers such as the insula and cingulate cortex (central command). This results in a response that is proportional to the intensity of the physical activity or perceived requirement for the physical activity [",
"    <a class=\"abstract\" href=\"UTD.htm?3/45/3799/abstract/30\">",
"     30",
"    </a>",
"    ]. Baroreflex activation due to transient hypotension causes the later increase in heart rate [",
"    <a class=\"abstract\" href=\"UTD.htm?3/45/3799/abstract/31,32\">",
"     31,32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The heart rate and blood pressure return to a new baseline after approximately 30 seconds. The \"30:15 ratio\" assesses this physiologic response by measuring the ratio of the heart rate increase that occurs at approximately 15 seconds after standing to the relative bradycardia that occurs at approximately the 30 seconds after standing [",
"    <a class=\"abstract\" href=\"UTD.htm?3/45/3799/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. When cardiovagal function is deficient, the bradycardia does not occur. This ratio provides a measure of cardiac vagal function [",
"    <a class=\"abstract\" href=\"UTD.htm?3/45/3799/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One report dissected the components of the heart rate response to passive tilting by measuring the acceleration index (the shortest R-R interval after standing minus the baseline R-R interval, all divided by the baseline R-R interval) and the brake index (the longest R-R interval after standing minus the shortest R-R interval, all divided by the baseline R-R interval). It was suggested that the acceleration index provides a measure of baroreceptor-mediated vagal withdrawal, while the brake index assesses the vagal response to the sympathetic-mediated increase in peripheral resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?3/45/3799/abstract/35\">",
"     35",
"    </a>",
"    ]. However, others have suggested that R-R interval lengthening does not occur after passive tilting [",
"    <a class=\"abstract\" href=\"UTD.htm?3/45/3799/abstract/31,33\">",
"     31,33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is a low correlation between indices of the heart rate response to postural change and those of heart rate variability provoked by deep breathing (r = 0.14) suggesting different physiological mechanisms are involved [",
"    <a class=\"abstract\" href=\"UTD.htm?3/45/3799/abstract/36\">",
"     36",
"    </a>",
"    ]. Typical normal values for the 30:15 are as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?3/45/3799/abstract/12\">",
"     12",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      1.15 to 1.12 in 20 to 30-year-olds",
"     </li>",
"     <li>",
"      1.12 to 1.10 in 31 to 40-year-olds",
"     </li>",
"     <li>",
"      1.10 to 1.08 in 41 to 50-year-olds",
"     </li>",
"     <li>",
"      1.08 to 1.07 in 51 to 60-year-olds",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Lying down",
"    </span>",
"    &nbsp;&mdash;&nbsp;A related test measures the heart rate response to assuming the supine position. After lying down, there is a decrease in the R-R interval that is maximal around the third or fourth beat, which is followed by an increase in the R-R interval value (greater than the resting value) at approximately the 25th to 30th beat. Autonomic blockade studies with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/23/11640?source=see_link\">",
"     atropine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    have suggested that the initial R-R interval shortening is mediated by the vagus nerve, while the later lengthening is predominantly mediated by the sympathetic nervous system. The initial tachycardia is most likely a manifestation of the \"exercise\" or \"muscle-heart\" reflex [",
"    <a class=\"abstract\" href=\"UTD.htm?3/45/3799/abstract/37,38\">",
"     37,38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Squatting",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cardiovascular response to squatting has been measured in a group of controls and diabetic subjects [",
"    <a class=\"abstract\" href=\"UTD.htm?3/45/3799/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. In this test, subjects stand still for three minutes, squat down for one minute, and then stand up during inspiration. Squatting results in lengthening of the R-R interval that is abolished by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/23/11640?source=see_link\">",
"     atropine",
"    </a>",
"    , suggesting a vagal-mediated response; the shortening of the R-R interval that occurred after standing from a squatting position is attenuated by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    , suggesting mediation by sympathetic activation.",
"   </p>",
"   <p>",
"    In one report, a vagal ratio based upon this test (the ratio between the R-R interval mean before squatting and the longest R-R interval after squatting) was calculated [",
"    <a class=\"abstract\" href=\"UTD.htm?3/45/3799/abstract/39\">",
"     39",
"    </a>",
"    ]. The result was outside the 99 percent confidence interval in 42 percent of diabetic patients versus 1.3 percent of the controls. The results showed an inverse correlation with age.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Apneic facial immersion",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diving reflex in mammals is provoked by facial cooling and consists of bradycardia, apnea, decreased cardiac output, and vasoconstriction [",
"    <a class=\"abstract\" href=\"UTD.htm?3/45/3799/abstract/41\">",
"     41",
"    </a>",
"    ]. As a clinical test, the diving reflex assesses trigeminal-vagal-cardiac and trigeminal-sympathetic-vascular smooth muscle pathways and does not directly involve the baroreflex or its primary central connections [",
"    <a class=\"abstract\" href=\"UTD.htm?3/45/3799/abstract/42\">",
"     42",
"    </a>",
"    ]. The test can also be performed in uncooperative or unconscious patients [",
"    <a class=\"abstract\" href=\"UTD.htm?3/45/3799/abstract/43\">",
"     43",
"    </a>",
"    ]. However, some investigators suggest that this test does not add significantly to other measures of autonomic function [",
"    <a class=\"abstract\" href=\"UTD.htm?3/45/3799/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     LONG-TERM MEASURES OF HEART RATE VARIABILITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Large, irregular, and episodic changes in heart rate can occur in normal subjects. These changes were quantified using a threshold value of 50 milliseconds difference from the preceding R-R interval (NN50) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/45/3799/abstract/45\">",
"     45",
"    </a>",
"    ]. The number of such steps or \"R-R counts\" in normal subjects shows an inverse relationship with age and increases during sleep [",
"    <a class=\"abstract\" href=\"UTD.htm?3/45/3799/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/10/4264?source=see_link\">",
"     \"Heart rate variability: Technical aspects\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A reduced number of these steps was found in diabetic subjects with autonomic neuropathy, some diabetics without autonomic neuropathy, patients with cardiac transplants, and in some patients after a myocardial infarction [",
"    <a class=\"abstract\" href=\"UTD.htm?3/45/3799/abstract/46\">",
"     46",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/39/35449?source=see_link\">",
"     \"Heart rate variability: Uses other than after myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/22/10601?source=see_link\">",
"     \"Heart rate variability: Use after myocardial infarction\"",
"    </a>",
"    .) In particular, 24 percent of diabetic subjects with normal cardiovascular reflexes had 24-hour R-R counts that were below the lower 95 percent confidence limit for healthy controls related to age.",
"   </p>",
"   <p>",
"    Based upon these results, the authors suggested that this method of heart rate variability analysis was more sensitive than the conventional tests of cardiovascular reflexes. This measure and the related pNN50 (the proportion of differences in consecutive normal R-R intervals that are greater than 50 milliseconds) correlates with the rMSSD and power in the high frequency of the heart rate power spectrum (&gt;0.15 Hz) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/45/3799/abstract/9,47,48\">",
"     9,47,48",
"    </a>",
"    ].",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Freeman, R. Heart rate variability - the time domain. In: Clinical Autonomic Disorders, Low, PA (Ed), Little Brown, Boston 1997. p.297.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/45/3799/abstract/2\">",
"      Wheeler T, Watkins PJ. Cardiac denervation in diabetes. Br Med J 1973; 4:584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/45/3799/abstract/3\">",
"      Sundkvist, G, Almer, L, Lilja, B. Respiratory influence on heart rate in diabetes mellitus. Br Med J 1979; 1:924.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/45/3799/abstract/4\">",
"      Ewing DJ, Borsey DQ, Bellavere F, Clarke BF. Cardiac autonomic neuropathy in diabetes: comparison of measures of R-R interval variation. Diabetologia 1981; 21:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/45/3799/abstract/5\">",
"      Gundersen HJ, Neubauer B. A long-term diabetic autonomic nervous abnormality. Reduced variations in resting heart rate measured by a simple and sensitive method. Diabetologia 1977; 13:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/45/3799/abstract/6\">",
"      Weinberg CR, Pfeifer MA. An improved method for measuring heart-rate variability: assessment of cardiac autonomic function. Biometrics 1984; 40:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/45/3799/abstract/7\">",
"      Genovely H, Pfeifer MA. RR-variation: the autonomic test of choice in diabetes. Diabetes Metab Rev 1988; 4:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/45/3799/abstract/8\">",
"      The effect of intensive diabetes therapy on the development and progression of neuropathy. The Diabetes Control and Complications Trial Research Group. Ann Intern Med 1995; 122:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/45/3799/abstract/9\">",
"      Bigger JT Jr, Albrecht P, Steinman RC, et al. Comparison of time- and frequency domain-based measures of cardiac parasympathetic activity in Holter recordings after myocardial infarction. Am J Cardiol 1989; 64:536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/45/3799/abstract/10\">",
"      Malpas SC, Maling TJ. Heart-rate variability and cardiac autonomic function in diabetes. Diabetes 1990; 39:1177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/45/3799/abstract/11\">",
"      Harry JD, Freeman R. Determining heart-rate variability: comparing methodologies using computer simulations. Muscle Nerve 1993; 16:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/45/3799/abstract/12\">",
"      Ziegler D, Laux G, Dannehl K, et al. Assessment of cardiovascular autonomic function: age-related normal ranges and reproducibility of spectral analysis, vector analysis, and standard tests of heart rate variation and blood pressure responses. Diabet Med 1992; 9:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/45/3799/abstract/13\">",
"      Freeman R, Cohen RJ, Saul JP. Transfer function analysis of respiratory sinus arrhythmia: a measure of autonomic function in diabetic neuropathy. Muscle Nerve 1995; 18:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/45/3799/abstract/14\">",
"      Eckberg DL. Human sinus arrhythmia as an index of vagal cardiac outflow. J Appl Physiol 1983; 54:961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/45/3799/abstract/15\">",
"      Brown TE, Beightol LA, Koh J, Eckberg DL. Important influence of respiration on human R-R interval power spectra is largely ignored. J Appl Physiol 1993; 75:2310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/45/3799/abstract/16\">",
"      Mackay JD. Respiratory sinus arrhythmia in diabetic neuropathy. Diabetologia 1983; 24:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/45/3799/abstract/17\">",
"      Cooke WH, Cox JF, Diedrich AM, et al. Controlled breathing protocols probe human autonomic cardiovascular rhythms. Am J Physiol 1998; 274:H709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/45/3799/abstract/18\">",
"      Taylor JA, Myers CW, Halliwill JR, et al. Sympathetic restraint of respiratory sinus arrhythmia: implications for vagal-cardiac tone assessment in humans. Am J Physiol Heart Circ Physiol 2001; 280:H2804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/45/3799/abstract/19\">",
"      Low PA, Denq JC, Opfer-Gehrking TL, et al. Effect of age and gender on sudomotor and cardiovagal function and blood pressure response to tilt in normal subjects. Muscle Nerve 1997; 20:1561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/45/3799/abstract/20\">",
"      Benarroch EE, Opfer-Gehrking TL, Low PA. Use of the photoplethysmographic technique to analyze the Valsalva maneuver in normal man. Muscle Nerve 1991; 14:1165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/45/3799/abstract/21\">",
"      Smith SA. Diagnostic value of the Valsalva ratio reduction in diabetic autonomic neuropathy: use of an age-related normal range. Diabet Med 1984; 1:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/45/3799/abstract/22\">",
"      Levin AB. A simple test of cardiac function based upon the heart rate changes induced by the Valsalva maneuver. Am J Cardiol 1966; 18:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/45/3799/abstract/23\">",
"      Baldwa VS, Ewing DJ. Heart rate response to Valsalva manoeuvre. Reproducibility in normals, and relation to variation in resting heart rate in diabetics. Br Heart J 1977; 39:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/45/3799/abstract/24\">",
"      Ferrer MT, Kennedy WR, Sahinen F. Baroreflexes in patients with diabetes mellitus. Neurology 1991; 41:1462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/45/3799/abstract/25\">",
"      Eckberg DL. Parasympathetic cardiovascular control in human disease: a critical review of methods and results. Am J Physiol 1980; 239:H581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/45/3799/abstract/26\">",
"      Low PA, Walsh JC, Huang CY, McLeod JG. The sympathetic nervous system in alcoholic neuropathy. A clinical and pathological study. Brain 1975; 98:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/45/3799/abstract/27\">",
"      Ewing DJ, Campbell IW, Burt AA, Clarke BF. Vascular reflexes in diabetic autonomic neuropathy. Lancet 1973; 2:1354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/45/3799/abstract/28\">",
"      Persson A, Solders G. R-R variations, a test of autonomic dysfunction. Acta Neurol Scand 1983; 67:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/45/3799/abstract/29\">",
"      van Lieshout JJ, Wieling W, Wesseling KH, Karemaker JM. Pitfalls in the assessment of cardiovascular reflexes in patients with sympathetic failure but intact vagal control. Clin Sci (Lond) 1989; 76:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/45/3799/abstract/30\">",
"      Williamson JW, McColl R, Mathews D. Evidence for central command activation of the human insular cortex during exercise. J Appl Physiol 2003; 94:1726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/45/3799/abstract/31\">",
"      Borst C, Wieling W, van Brederode JF, et al. Mechanisms of initial heart rate response to postural change. Am J Physiol 1982; 243:H676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/45/3799/abstract/32\">",
"      Sprangers RL, Wesseling KH, Imholz AL, et al. Initial blood pressure fall on stand up and exercise explained by changes in total peripheral resistance. J Appl Physiol 1991; 70:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/45/3799/abstract/33\">",
"      Ewing DJ, Hume L, Campbell IW, et al. Autonomic mechanisms in the initial heart rate response to standing. J Appl Physiol 1980; 49:809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/45/3799/abstract/34\">",
"      Ewing DJ, Campbell IW, Murray A, et al. Immediate heart-rate response to standing: simple test for autonomic neuropathy in diabetes. Br Med J 1978; 1:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/45/3799/abstract/35\">",
"      Sundkvist G, Lilja B, Alm&eacute;r LO. Abnormal diastolic blood pressure and heart rate reactions to tilting in diabetes mellitus. Diabetologia 1980; 19:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/45/3799/abstract/36\">",
"      Wieling W, van Brederode JF, de Rijk LG, et al. Reflex control of heart rate in normal subjects in relation to age: a data base for cardiac vagal neuropathy. Diabetologia 1982; 22:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/45/3799/abstract/37\">",
"      Bellavere F, Ewing DJ. Autonomic control of the immediate heart rate response to lying down. Clin Sci (Lond) 1982; 62:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/45/3799/abstract/38\">",
"      Bellavere F, Cardone C, Ferri M, et al. Standing to lying heart rate variation. A new simple test in the diagnosis of diabetic autonomic neuropathy. Diabet Med 1987; 4:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/45/3799/abstract/39\">",
"      Marfella R, Giugliano D, di Maro G, et al. The squatting test. A useful tool to assess both parasympathetic and sympathetic involvement of the cardiovascular autonomic neuropathy in diabetes. Diabetes 1994; 43:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/45/3799/abstract/40\">",
"      Marfella R, Salvatore T, Giugliano D, et al. Detection of early sympathetic cardiovascular neuropathy by squatting test in NIDDM. Diabetes Care 1994; 17:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/45/3799/abstract/41\">",
"      Finley JP, Bonet JF, Waxman MB. Autonomic pathways responsible for bradycardia on facial immersion. J Appl Physiol 1979; 47:1218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/45/3799/abstract/42\">",
"      Eckberg DL, Mohanty SK, Raczkowska M. Trigeminal-baroreceptor reflex interactions modulate human cardiac vagal efferent activity. J Physiol 1984; 347:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/45/3799/abstract/43\">",
"      Khurana RK, Watabiki S, Hebel JR, et al. Cold face test in the assessment of trigeminal-brainstem-vagal function in humans. Ann Neurol 1980; 7:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/45/3799/abstract/44\">",
"      Bennett T, Hosking DJ, Hampton JR. Cardiovascular reflex responses to apnoeic face immersion and mental stress in diabetic subjects. Cardiovasc Res 1976; 10:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/45/3799/abstract/45\">",
"      Ewing DJ, Neilson JM, Travis P. New method for assessing cardiac parasympathetic activity using 24 hour electrocardiograms. Br Heart J 1984; 52:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/45/3799/abstract/46\">",
"      Ewing DJ, Neilson JM, Shapiro CM, et al. Twenty four hour heart rate variability: effects of posture, sleep, and time of day in healthy controls and comparison with bedside tests of autonomic function in diabetic patients. Br Heart J 1991; 65:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/45/3799/abstract/47\">",
"      Kleiger RE, Bigger JT, Bosner MS, et al. Stability over time of variables measuring heart rate variability in normal subjects. Am J Cardiol 1991; 68:626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/45/3799/abstract/48\">",
"      Bigger JT Jr, Fleiss JL, Steinman RC, et al. Correlations among time and frequency domain measures of heart period variability two weeks after acute myocardial infarction. Am J Cardiol 1992; 69:891.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5273 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-203.80.222.8-D1AB04EF24-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_45_3799=[""].join("\n");
var outline_f3_45_3799=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      SHORT-TERM MEASURES OF HEART RATE VARIABILITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Respiration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Valsalva maneuver",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Assumption of upright posture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Lying down",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Squatting",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Apneic facial immersion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      LONG-TERM MEASURES OF HEART RATE VARIABILITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/10/4264?source=related_link\">",
"      Heart rate variability: Technical aspects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/22/10601?source=related_link\">",
"      Heart rate variability: Use after myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/39/35449?source=related_link\">",
"      Heart rate variability: Uses other than after myocardial infarction",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_45_3800="Diagnosis and management of massive fetomaternal hemorrhage";
var content_f3_45_3800=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Diagnosis and management of massive fetomaternal hemorrhage",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/45/3800/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/45/3800/contributors\">",
"     Kenneth J Moise Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/45/3800/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/45/3800/contributors\">",
"     Charles J Lockwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/45/3800/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/45/3800/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?3/45/3800/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 21, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the placenta is considered a barrier separating the maternal and fetal circulations, bidirectional trafficking of cells across the placenta is a physiological event [",
"    <a class=\"abstract\" href=\"UTD.htm?3/45/3800/abstract/1\">",
"     1",
"    </a>",
"    ]. Most investigations have focused upon fetal nucleated blood cells, which have been identified in minute quantities in the maternal circulation throughout normal pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?3/45/3800/abstract/2\">",
"     2",
"    </a>",
"    ]. Sometimes, however, fetomaternal hemorrhage (FMH) involves a large volume of blood. This topic will review the clinical presentation, diagnosis, and management of pregnancies complicated by massive FMH.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no universally accepted definition of the volume of fetal erythrocytes in the maternal circulation that constitutes a massive FMH; volumes of 10 to 150 mL have been proposed [",
"    <a class=\"abstract\" href=\"UTD.htm?3/45/3800/abstract/3\">",
"     3",
"    </a>",
"    ]. Fetal blood volume is about 100",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    fetal weight [",
"    <a class=\"abstract\" href=\"UTD.htm?3/45/3800/abstract/4\">",
"     4",
"    </a>",
"    ], ranging from 117",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    at 18 weeks to 93",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    at 31 weeks gestation [",
"    <a class=\"abstract\" href=\"UTD.htm?3/45/3800/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A better approach to assessing the magnitude of FMH is to estimate the percentage of the fetal blood volume represented by the FMH. Looked at in this way, a FMH of 20",
"    <span class=\"nowrap\">",
"     mL/kg,",
"    </span>",
"    which represents 20 percent of the fetoplacental blood volume, is considered massive because it has been associated with significant",
"    <span class=\"nowrap\">",
"     fetal/neonatal",
"    </span>",
"    morbidity or mortality (see",
"    <a class=\"local\" href=\"#H20\">",
"     'Prognosis'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    Experiments in sheep show that the rapidity of fetal blood loss is an additional major factor influencing morbidity and mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?3/45/3800/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. Massive FMH is more likely to be fatal if the blood loss occurs over minutes rather than hours, days, or weeks. Although a critical prognostic factor, the rate of fetomaternal bleeding in human pregnancies is generally impossible to assess clinically, unless there are signs of chronic anemia, such as hydrops.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     INCIDENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of FMH greater than 20 to 30 mL at delivery is estimated to be about 1 in 200 to 300 deliveries [",
"    <a class=\"abstract\" href=\"UTD.htm?3/45/3800/abstract/3,8,9\">",
"     3,8,9",
"    </a>",
"    ]. FMH greater than 80 mL and greater than 150 mL is estimated to occur in 1 in 1000 deliveries and 1 in 5000 deliveries, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?3/45/3800/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These estimates of massive FMH were derived from two large series:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One series consisted of 48 patients with FMH &gt;20 mL identified among 45,180 deliveries over an eight-year period at two hospitals [",
"      <a class=\"abstract\" href=\"UTD.htm?3/45/3800/abstract/9\">",
"       9",
"      </a>",
"      ]. Sixty percent of the cases were identified because of routine postpartum Kleihauer-Betke testing of Rh(D)-negative women (n = 6777 deliveries); the other 40 percent were identified by Kleihauer-Betke testing in women in whom FMH was suspected because of maternal abdominal trauma, fetal distress, fetal death, or neonatal pallor.",
"      <br/>",
"      <br/>",
"      In the routinely tested Rh(D)-negative population, the incidence of FMH &gt;20 mL was 4.6 per 1000 live births (ie, 1 in 217 live births); for FMH &gt;30 mL, the incidence was 3.8 per 1000 live births (1 in 263); and for FMH &gt;80 mL, the incidence was 0.7 per 1000 live births (1 in 1429).",
"     </li>",
"     <li>",
"      In the other series, 30,944 Rh(D)-negative women underwent Kleihauer-Betke screening at the time of delivery (see",
"      <a class=\"local\" href=\"#H7\">",
"       'Kleihauer-Betke'",
"      </a>",
"      below)&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?3/45/3800/abstract/3\">",
"       3",
"      </a>",
"      ]. The incidence of FMH &gt;80 mL was 1 in 1146 deliveries and the incidence of FMH &gt;150 mL was 1 in 2813 deliveries (or 0.9 and 0.2 per 1000 deliveries, respectively).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Massive FMH may result from trauma or occur spontaneously. Traumatic injuries to the placental interface are typically caused by invasive diagnostic procedures (eg, amniocentesis, chorion villus biopsy, fetoscopy) or blunt abdominal trauma (eg, external cephalic version, motor vehicle crash, fall). Other reported risk factors for large FMH include multiple gestation, nuchal cord, and low birth weight [",
"    <a class=\"abstract\" href=\"UTD.htm?3/45/3800/abstract/10,11\">",
"     10,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Spontaneous FMH is defined as hemorrhage with no antecedent history of trauma and no",
"    <span class=\"nowrap\">",
"     clinical/histopathological",
"    </span>",
"    evidence of abruption. One of the largest series of FMHs &gt;50 mL (n = 134 cases) reported a cause could not be determined in 82 percent, which suggests most massive FMHs are spontaneous [",
"    <a class=\"abstract\" href=\"UTD.htm?3/45/3800/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pathogenesis of FMH is unclear. A histological study of placentas observed that the presence of parenchymal and retroplacental hemorrhage, intervillous thrombi, and infarction increased the likelihood that fetal cells would be found in the maternal circulation and that the extent of the abnormality correlated with the size of the hemorrhage [",
"    <a class=\"abstract\" href=\"UTD.htm?3/45/3800/abstract/13\">",
"     13",
"    </a>",
"    ]. However, many questions remain about the origin of these lesions and the factors that determine the number and volume of bleeding episodes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Massive FMH occurs in the second or third trimester and can be either acute or chronic (ie, intermittent recurrent FMH). The mother herself is usually asymptomatic, although symptoms suggestive of a transfusion reaction (eg, fever, chills, nausea) have been described in case reports [",
"    <a class=\"abstract\" href=\"UTD.htm?3/45/3800/abstract/14,15\">",
"     14,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Decreased or absent fetal movement is the most common presentation antepartum. When fetal heart rate monitoring is performed to evaluate fetal well-being, a sinusoidal fetal heart rate pattern (",
"    <a class=\"graphic graphic_waveform graphicRef61189 \" href=\"UTD.htm?12/38/12902\">",
"     waveform 1",
"    </a>",
"    ) or recurrent late decelerations may be observed [",
"    <a class=\"abstract\" href=\"UTD.htm?3/45/3800/abstract/16\">",
"     16",
"    </a>",
"    ]. Fetal tachycardia has also been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?3/45/3800/abstract/17\">",
"     17",
"    </a>",
"    ]. Ultrasound assessment may yield a low biophysical profile score. In some cases, however, a massive FMH may not be suspected until fetal demise has been identified [",
"    <a class=\"abstract\" href=\"UTD.htm?3/45/3800/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Over time, chronic FMH can lead to persistent fetal anemia and hydrops fetalis. The triad of decreased fetal movement, sinusoidal fetal heart rate pattern, and hydrops fetalis are late signs of massive chronic FMH [",
"    <a class=\"abstract\" href=\"UTD.htm?3/45/3800/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In anemic neonates, increased production of red blood cell precursors and increased circulating reticulocyte counts suggest FMH occurred one to two days prior to birth [",
"    <a class=\"abstract\" href=\"UTD.htm?3/45/3800/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These issues were illustrated in a review of 120 cases of FMH &gt;50 mL noted before and after delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?3/45/3800/abstract/12\">",
"     12",
"    </a>",
"    ]. The following presentations were described: anemia at birth (35.2 percent of cases), decreased or absent fetal movement (26.8 percent), unexpected stillbirth (12.5 percent), hydrops (7.5 percent), fetal distress (6.6 percent), intrauterine growth restriction (3.3 percent), and one or two cases each of sinusoidal fetal heart rate pattern, fetal atrial fibrillation, and maternal transfusion reaction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     LABORATORY EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two maternal assays are available for detecting FMH: the Kleihauer-Betke test and flow cytometry. Both are based on identification of fetal red blood cells by the presence of hemoglobin F, the predominant fetal hemoglobin. However, adult red blood cells may also contain fetal hemoglobin; these cells are called F cells, and can cause current assays performed on maternal blood samples to over-estimate the volume of FMH. This is especially important in some hematological disorders, such as sickle cell disease, which can be associated with persistence of hemoglobin F in a large number of cells. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/29/23001?source=see_link\">",
"     \"Structure and function of normal human hemoglobins\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These assays show the volume of fetal blood in the maternal circulation at a point in time, and thus do not necessarily indicate the volume of blood loss over time if bleeding was chronic or occurred on multiple occasions. The lifespan of the fetal erythrocyte is 100 days, but is much shorter in the maternal circulation if there is ABO or Rhesus incompatibility.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Kleihauer-Betke",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Kleihauer-Betke test is the main diagnostic test used for detection and quantitation of FMH [",
"    <a class=\"abstract\" href=\"UTD.htm?3/45/3800/abstract/19\">",
"     19",
"    </a>",
"    ]. Red blood cells from the maternal circulation are fixed to a slide that is then exposed to an acidic pH solution. Adult red blood cells become \"ghost\" cells since hemoglobin A is soluble and eluted across membrane defects at a low pH. Fetal red blood cells remain pink because hemoglobin F is stable at pHs in this range (",
"    <a class=\"graphic graphic_picture graphicRef71762 \" href=\"UTD.htm?2/36/2624\">",
"     picture 1",
"    </a>",
"    ). A laboratory technician looking through a microscope counts a minimum of 2000 cells (typically 8 to 10 fields at 250X magnification) and reports the result as the percentage of fetal red cells in the total sample. The volume of fetal whole blood (mL) in the maternal circulation is: (% fetal cells) X (maternal hematocrit [%] divided by fetal hematocrit [%]) X (maternal blood volume mL).",
"   </p>",
"   <p>",
"    In the usual clinical scenario, the maternal blood volume and the fetal hematocrit are not known and most laboratories do not request the maternal hematocrit for the calculation. The maternal blood volume is often assumed to be 5000 mL, yielding the following formula to calculate the volume of fetal whole blood (mL) in the maternal circulation: (% fetal cells) X 5000 mL. Thus, if the Kleihauer-Betke result is 0.1 percent, the FMH calculation is (0.001 X 5000) = 5 mL of fetal whole blood.",
"   </p>",
"   <p>",
"    Since the maternal blood volume is not actually measured in either of these calculations, the clinician should consider the volume of FMH an estimate. Furthermore, patients who are smaller or larger than the mean would be expected to have circulating blood volumes smaller or larger than 5000 mLs. The same Kleihauer-Betke test result will overestimate the volume of FMH in a smaller woman and underestimate the volume of FMH in a larger woman. To address these concerns, the College of American Pathologists (CAP,",
"    <span class=\"nowrap\">",
"     file://",
"     <a class=\"external\" href=\"file://www.cap.org/\">",
"      www.cap.org",
"     </a>",
"     /apps/docs/committees/transfusionmedicine/RHIGCALe.zip)",
"    </span>",
"    provides a RhIg dose calculator that uses the percent fetal bleed and the mother&rsquo;s blood volume calculated from her height and weight to estimate the volume of fetal bleed and to recommend an appropriate number of vials of anti-D immune globulin [",
"    <a class=\"abstract\" href=\"UTD.htm?3/45/3800/abstract/20\">",
"     20",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Variations in the formula for estimating FMH and in the assumptions used in the calculating of FMH have been published. A comparison of these formulas when fetal cells comprised 3 percent of cells in the maternal sample yielded FMH estimates ranging from 108 to 162 mL [",
"    <a class=\"abstract\" href=\"UTD.htm?3/45/3800/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Flow cytometry",
"    </span>",
"    &nbsp;&mdash;&nbsp;Flow cytometry is another assay for detecting and quantitating FMH [",
"    <a class=\"abstract\" href=\"UTD.htm?3/45/3800/abstract/22\">",
"     22",
"    </a>",
"    ]. A monoclonal antibody to hemoglobin F is conjugated to a fluorochrome and used to detect fetal hemoglobin in permeabilized cells as they pass through the channel of a flow cytometer. Comparative analysis of flow cytometry and the Kleihauer-Betke test has shown that flow cytometry is more accurate, more reproducible, and less labor intensive [",
"    <a class=\"abstract\" href=\"UTD.htm?3/45/3800/abstract/23\">",
"     23",
"    </a>",
"    ]. For this reason, many laboratories are converting to this assay for the detection of FMH.",
"   </p>",
"   <p>",
"    Calculation of FMH using flow cytometry is subject to the same limitations as the Kleihauer-Betke test: inability to measure the maternal blood volume and interference with persistence of fetal hemoglobin in adult red blood cells (known as F cells). Dual parameter flow cytometry can alleviate the issue with maternal F cells noted in such disease states as hemoglobinopathies and thalassemias. A second antibody is used to detect unique erythrocyte antigens to fetal red cells such as carbonic anhydrase. Only cells that are positive for both hemoglobin F and carbonic anhydrase are gated for a positive response. The flow cytometry equation for calculating the volume (mL) of fetal packed red blood cells in the maternal circulation is [",
"    <a class=\"abstract\" href=\"UTD.htm?3/45/3800/abstract/22\">",
"     22",
"    </a>",
"    ]: (% positive events) X (1800 mL) divided by 100 X",
"    <span class=\"nowrap\">",
"     (122/100);",
"    </span>",
"    where 1800 mL is the estimated average maternal red blood cell volume based on a maternal hematocrit of 36 percent and",
"    <span class=\"nowrap\">",
"     122/100",
"    </span>",
"    is an adjustment to take into account that fetal red blood cells are usually about 20 percent larger than adult red blood cells. Multiplying this value by a factor of two yields the volume (mL) of whole blood FMH, since the normal fetal hematocrit is approximately 50 percent. As an example, a flow cytometry result of 0.1 percent positive events would result in the following calculation: (0.1 X",
"    <span class=\"nowrap\">",
"     1800)/100",
"    </span>",
"    = 1.8 X",
"    <span class=\"nowrap\">",
"     122/100",
"    </span>",
"    = 2.2 mL X 2 = 4.4 mL whole blood volume fetomaternal hemorrhage.",
"   </p>",
"   <p>",
"    Some experts have recommended that the estimated FMH should be calculated as a percentage of the estimated total fetal blood volume (see",
"    <a class=\"local\" href=\"#H20\">",
"     'Prognosis'",
"    </a>",
"    below)&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?3/45/3800/abstract/9\">",
"     9",
"    </a>",
"    ]. The latter can be calculated by multiplying the estimated fetal weight in kilograms (based on ultrasound parameters) by 85",
"    <span class=\"nowrap\">",
"     mL/kg,",
"    </span>",
"    which is the fetal blood volume per kilogram fetal weight. The percent of fetal blood volume represented by the FMH would be (whole blood volume of FMH in mL) divided by (estimated fetal weight in kg) X (85",
"    <span class=\"nowrap\">",
"     ml/kg).",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR DIAGNOSTIC EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Testing for FMH is reasonable in certain clinical settings:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Fetal demise",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evaluation for FMH should be part of the diagnostic evaluation of unexplained intrauterine fetal demise after 20 weeks of gestation [",
"    <a class=\"abstract\" href=\"UTD.htm?3/45/3800/abstract/24\">",
"     24",
"    </a>",
"    ]. Fetal demise has been attributed to spontaneous massive FMH in 1.6 to 13.8 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?3/45/3800/abstract/9,18\">",
"     9,18",
"    </a>",
"    ]. A FMH greater than 20 to 25",
"    <span class=\"nowrap\">",
"     mL/kg,",
"    </span>",
"    and especially greater than 40",
"    <span class=\"nowrap\">",
"     mL/kg,",
"    </span>",
"    is suggestive of FMH as the cause of death (see",
"    <a class=\"local\" href=\"#H20\">",
"     'Prognosis'",
"    </a>",
"    below). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/36/31306?source=see_link\">",
"     \"Incidence, etiology, and prevention of stillbirth\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/59/38839?source=see_link\">",
"     \"Evaluation of stillbirth\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Decreased fetal movement",
"    </span>",
"    &nbsp;&mdash;&nbsp;The basic evaluation of pregnancies complicated by persistent decreased fetal movement includes review of the prenatal record for possible causes, a nonstress test, and ultrasound examination. Some clinicians suggest obtaining a Kleihauer-Betke (or flow cytometry) test in all cases of persistently decreased fetal activity, but the utility of this approach is unclear if fetal evaluation is otherwise normal [",
"    <a class=\"abstract\" href=\"UTD.htm?3/45/3800/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/37/15959?source=see_link\">",
"     \"Evaluation of decreased fetal movements\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Sinusoidal FHR or hydrops fetalis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fetal anemia should be suspected if a sinusoidal fetal heart rate (FHR) pattern or hydrops fetalis is identified. In preterm gestations, the peak systolic velocity (PSV) of the middle cerebral artery (MCA) should be determined with Doppler ultrasound. A MCA-PSV value greater than 1.5 multiples of the median (MoM) strongly correlates with moderate to severe fetal anemia [",
"    <a class=\"abstract\" href=\"UTD.htm?3/45/3800/abstract/25\">",
"     25",
"    </a>",
"    ]. If fetal anemia is suggested by the results of Doppler ultrasound, then the cause of the anemia should be determined.",
"   </p>",
"   <p>",
"    A Kleihauer-Betke (or flow cytometry) test and screening for red blood cell antibodies are an appropriate initial approach for excluding FMH and hemolytic disease of the",
"    <span class=\"nowrap\">",
"     fetus/newborn",
"    </span>",
"    as causes of the fetal anemia. If the cause of the anemia is still unclear, evaluation for defective fetal red blood cell production or fetal production of abnormal hemoglobins is indicated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/21/5464?source=see_link&amp;anchor=H11#H11\">",
"     \"Management of pregnancy complicated by Rhesus (Rh) alloimmunization\", section on 'Middle cerebral artery-peak systolic velocity'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/37/34393?source=see_link&amp;anchor=H19#H19\">",
"     \"Nonimmune hydrops fetalis\", section on 'Anemia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These patients are treated by intrauterine transfusion or delivery, depending on gestational age (see",
"    <a class=\"local\" href=\"#H17\">",
"     'Management of spontaneous FMH'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Nonreassuring fetal testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Decreased fetal activity with nonreassuring fetal testing typically requires urgent delivery. If the neonate is anemic, laboratory evaluation for the cause, including FMH, is appropriate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Indeterminate fetal testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Decreased fetal activity and indeterminate fetal testing requires continued surveillance and evaluation to determine the cause and whether fetal testing will become reassuring or nonreassuring. There is no evidence on which to base a recommendation for or against routine antenatal evaluation for FMH in these patients. It is a reasonable option if there are any findings suggestive of FMH or fetal anemia or if no other reason is found for the indeterminate test results.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Maternal abdominal trauma",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no consensus as to whether all pregnant women who have experienced abdominal trauma should undergo routine testing for FMH. In one study, the incidence of a positive Kleihauer-Betke test among 151 pregnant women in the third trimester with varying severity of trauma was only 2.6 percent, which was not significantly different from the background rate in the general obstetrical population (low-risk gravid women at the time of routine screening for gestational diabetes) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/45/3800/abstract/26\">",
"     26",
"    </a>",
"    ]. In this series, no patient with a positive Kleihauer-Betke test had clinical evidence of an abruption or a nonreassuring fetal heart rate pattern. However, others have reported high rates of FMH (four- to five-fold higher than the background rate), especially in women with physical evidence of trauma, anterior placentae, or symptoms (eg, uterine tenderness, fetal heart rate abnormalities, contractions) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/45/3800/abstract/27-31\">",
"     27-31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These data suggest that testing may be cost-effective in symptomatic Rh(D)-negative women after 20 weeks of gestation since a massive FMH, although rare, would necessitate extra vials of anti-D-immune globulin [",
"    <a class=\"abstract\" href=\"UTD.htm?3/45/3800/abstract/28,32\">",
"     28,32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/44/40648?source=see_link\">",
"     \"Prevention of Rh(D) alloimmunization\"",
"    </a>",
"    .) The value of this information in Rh(D)-positive women with reassuring fetal testing is unproven.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Unexplained neonatal anemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;FMH should be considered in the differential diagnosis of neonatal anemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     MANAGEMENT OF SPONTANEOUS FMH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonreassuring fetal testing typically requires urgent delivery. Our approach to suspected spontaneous FMH with reassuring fetal testing is illustrated in the algorithm (",
"    <a class=\"graphic graphic_algorithm graphicRef73675 \" href=\"UTD.htm?42/53/43856\">",
"     algorithm 1",
"    </a>",
"    ). There are no high quality data to guide decision-making in these pregnancies. Management is based on fetal assessment and gestational age, taking into account the morbidity of prematurity, the morbidity of in utero therapy, and the uncertain clinical course of expectant management.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Massive hemorrhage/moderate to severe anemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;For pregnancies greater than 32 weeks of gestation with FMH greater than 20 percent of the fetal blood volume or MCA-PSV &ge;1.5 MOMs, we, and others, suggest immediate cesarean delivery, with blood available for prompt neonatal transfusion [",
"    <a class=\"abstract\" href=\"UTD.htm?3/45/3800/abstract/33\">",
"     33",
"    </a>",
"    ]. The morbidity of prematurity at this gestational age is probably outweighed by the risks of in utero transfusion or recurrent FMH during expectant management.",
"   </p>",
"   <p>",
"    For more preterm gestations, especially with severe anemia (eg, hydrops fetalis), an intravascular intrauterine transfusion (IVT) of donor red blood cells can acutely correct the fetal anemia and is probably preferable to subjecting the fetus to the risks of preterm birth [",
"    <a class=\"abstract\" href=\"UTD.htm?3/45/3800/abstract/34\">",
"     34",
"    </a>",
"    ]. Antenatal steroid therapy to enhance fetal lung maturity is suggested when a viable gestational age has been attained. Subsequent transfusions may be needed, but timing is difficult to determine after a transfusion given the uncertainty in diagnosis of ongoing FMH and in Doppler assessment of fetal anemia because transfused cells contain adult hemoglobin and thus are not detected by these tests. Continued hospitalization with daily MCA-PSV Dopplers and fetal heart rate monitoring is reasonable until intrauterine transfusions are no longer deemed necessary. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/57/13210?source=see_link\">",
"     \"Intrauterine fetal transfusion of red blood cells\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A review of chronic massive FMH with fetal hydrops treated by IVT reported overall perinatal survival in 12 of 13 cases (92 percent survival) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/45/3800/abstract/33\">",
"     33",
"    </a>",
"    ]. Two fetuses were delivered the same day as IVT and two others delivered within one week. In five cases, resolution of the fetal anemia and significant prolongation of the pregnancy occurred after one IVT. In the other cases, recurrent fetal anemia occurred several days after the initial IVT and up to five procedures were performed. The mean prolongation of the pregnancy was six weeks (range: 0 days to 16.6 weeks). Although these results are promising, the series is small and other clinicians have had unsuccessful outcomes, including perinatal death and long-term disability [",
"    <a class=\"abstract\" href=\"UTD.htm?3/45/3800/abstract/21\">",
"     21",
"    </a>",
"    ]. Therefore, use of such therapy should be limited to centers with experience in both serial middle cerebral artery Doppler assessment and intravascular intrauterine transfusions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Small hemorrhage/no or mild anemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pregnancies with FMH less than 20 percent of the fetal blood volume or MCA-PSV &lt;1.5 MOMs can be followed expectantly as long as nonstress testing is reassuring. Antenatal steroids to enhance fetal lung maturity are suggested. We evaluate undelivered pregnancies daily for one week for evidence of chronic FMH. Recurrence of FMH should be suspected if there is an increasing percentage of fetal cells in the maternal circulation on Kleihauer-Betke testing or flow cytometry or increasing velocity in the MCA-PSV. Repeated IVTs are unlikely to be successful in these cases due to the ongoing FMH; premature delivery is probably a more reasonable option.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5478147\">",
"    <span class=\"h2\">",
"     Anti-D immune globulin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women who are Rh(D)-negative should receive anti-D immune globulin. The dose should be determined in consultation with the blood bank when there has been a large fetomaternal hemorrhage. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/44/40648?source=see_link&amp;anchor=H5478312#H5478312\">",
"     \"Prevention of Rh(D) alloimmunization\", section on 'Evaluation and management of large fetomaternal hemorrhages'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Perinatal prognosis depends upon the acuity of the FMH, as well as the volume of the hemorrhage. Reported morbidity and mortality rates were derived from case reports and case series involving a range of gestational ages, both acute and chronic bleeds, and wide diversity in clinical presentation and management (in utero transfusion, expectant management, or early delivery).",
"   </p>",
"   <p>",
"    The range of outcomes in the literature is illustrated by the following examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a French study, the fetal death rate was 25 percent (two of eight fetuses) for FMH 40 to 80",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      and 66 percent (four of six fetuses) for FMH &ge;80",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      (fetoplacental blood volume averages about 100",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      fetal weight [",
"      <a class=\"abstract\" href=\"UTD.htm?3/45/3800/abstract/4,5\">",
"       4,5",
"      </a>",
"      ]).",
"      <br/>",
"      <br/>",
"      Morbidity occurred primarily in the 23 fetuses calculated to have bled &ge;20",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      (ie, &gt;20 percent of fetoplacental blood volume) and included: induced preterm delivery (17 percent), admission to the neonatal intensive care unit (35 percent), and neonatal transfusion (22 percent).",
"     </li>",
"     <li>",
"      For FMH &ge;150 mL, pooled data from two studies yielded a perinatal death rate of 37 percent (25 of 67) [",
"      <a class=\"abstract\" href=\"UTD.htm?3/45/3800/abstract/3,8\">",
"       3,8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A review of 134 cases of FMH &gt;50 mL noted that 13 liveborns had evidence of neurologic dysfunction, 10 had respiratory distress syndrome, 7 had persistent pulmonary hypertension, 4 developed disseminated intravascular coagulation, and 2 each developed pulmonary hemorrhage, cardiomegaly, and renal dysfunction [",
"      <a class=\"abstract\" href=\"UTD.htm?3/45/3800/abstract/12\">",
"       12",
"      </a>",
"      ]. Seventeen intrauterine fetal transfusions were performed in nine fetuses, eight of whom survived.",
"     </li>",
"     <li>",
"      Long-term pediatric outcome after massive FMH is less well described. In a series of 14 patients, one child developed quadriplegia [",
"      <a class=\"abstract\" href=\"UTD.htm?3/45/3800/abstract/2\">",
"       2",
"      </a>",
"      ]. In the French series cited above [",
"      <a class=\"abstract\" href=\"UTD.htm?3/45/3800/abstract/9\">",
"       9",
"      </a>",
"      ], 42 children were delivered of pregnancies complicated by &ge;20 mL FMH and 31 children were available for follow-up at a median age of 59 months (range: 18 to 107 months) [",
"      <a class=\"abstract\" href=\"UTD.htm?3/45/3800/abstract/9\">",
"       9",
"      </a>",
"      ]. No neurologic sequelae were noted in this series; however, the authors acknowledged their small sample size and a resulting wide confidence interval to detect poor outcome (95% CI: 0-11.6 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     RECURRENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recurrent significant FMH in successive pregnancies has been described in case reports [",
"    <a class=\"abstract\" href=\"UTD.htm?3/45/3800/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. There is no evidence on which to base a recommendation for following these women. Attention to fetal activity and prompt evaluation of decreased fetal activity is a reasonable approach [",
"    <a class=\"abstract\" href=\"UTD.htm?3/45/3800/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Massive fetomaternal hemorrhage (FMH) may occur spontaneously or as a result of trauma. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Fetomaternal bleeding may be acute or chronic. Signs of massive FMH include persistent decreased fetal movement, sinusoidal fetal heart rate pattern, recurrent late decelerations, hydrops fetalis, and fetal death. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest a maternal assay (Kleihauer-Betke stain or flow cytometry) to detect FMH in the evaluation of the pregnant patient who presents with a sinusoidal fetal heart rate pattern, hydrops fetalis, or unexplained fetal demise after 20 weeks of gestation. The utility of this test is unclear in women with persistent decreased fetal activity, but normal fetal heart rate and fetal ultrasound examination. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Indications for diagnostic evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The volume of fetal blood loss should be calculated as a percent of the estimated fetal blood volume. A loss of &ge;20 percent of the fetal blood volume can be fatal. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Laboratory evaluation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H20\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In a preterm gestation with sinusoidal fetal heart rate, hydrops or FMH &ge;20 percent of fetal blood volume, the peak systolic velocity (PSV) of the middle cerebral artery (MCA) should be determined with Doppler ultrasound. A MCA-PSV value greater than 1.5 multiples of the median (MoM) strongly correlates with moderate to severe fetal anemia. If fetal anemia is suggested by the results of Doppler ultrasound, then the cause of the anemia should be determined. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Sinusoidal FHR or hydrops fetalis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For pregnancies &ge;32 weeks of gestation with FMH &ge;20 percent of fetal blood volume or moderate to severe fetal anemia by Doppler, we suggest urgent delivery rather than intrauterine transfusion (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Management of spontaneous FMH'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For pregnancies &lt;32 weeks of gestation with FMH &ge;20 percent of fetal blood volume or moderate to severe fetal anemia by Doppler, we suggest intravascular fetal transfusion rather than urgent delivery (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Intrauterine transfusion can correct severe fetal anemia and thus avoid risks of very preterm birth. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Management of spontaneous FMH'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Small FMHs with only mild fetal anemia can be followed expectantly. We perform daily Kleihauer-Betke (or flow cytometry) tests, middle cerebral artery Doppler velocimetry, and fetal monitoring for one week and deliver the fetus if there is evidence of persistent FMH. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Management of spontaneous FMH'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/45/3800/abstract/1\">",
"      Bianchi DW, Romero R. Biological implications of bi-directional fetomaternal cell traffic: a summary of a National Institute of Child Health and Human Development-sponsored conference. J Matern Fetal Neonatal Med 2003; 14:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/45/3800/abstract/2\">",
"      Lo YM, Lau TK, Chan LY, et al. Quantitative analysis of the bidirectional fetomaternal transfer of nucleated cells and plasma DNA. Clin Chem 2000; 46:1301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/45/3800/abstract/3\">",
"      de Almeida V, Bowman JM. Massive fetomaternal hemorrhage: Manitoba experience. Obstet Gynecol 1994; 83:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/45/3800/abstract/4\">",
"      Leduc L, Moise KJ Jr, Carpenter RJ Jr, Cano LE. Fetoplacental blood volume estimation in pregnancies with Rh alloimmunization. Fetal Diagn Ther 1990; 5:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/45/3800/abstract/5\">",
"      Nicolaides KH, Clewell WH, Rodeck CH. Measurement of human fetoplacental blood volume in erythroblastosis fetalis. Am J Obstet Gynecol 1987; 157:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/45/3800/abstract/6\">",
"      Brace RA. Mechanisms of fetal blood volume restoration after slow fetal hemorrhage. Am J Physiol 1989; 256:R1040.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/45/3800/abstract/7\">",
"      Brace RA, Cheung CY. Fetal blood volume restoration following rapid fetal hemorrhage. Am J Physiol 1990; 259:H567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/45/3800/abstract/8\">",
"      Sebring ES, Polesky HF. Fetomaternal hemorrhage: incidence, risk factors, time of occurrence, and clinical effects. Transfusion 1990; 30:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/45/3800/abstract/9\">",
"      Rubod C, Deruelle P, Le Goueff F, et al. Long-term prognosis for infants after massive fetomaternal hemorrhage. Obstet Gynecol 2007; 110:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/45/3800/abstract/10\">",
"      Adeniji AO, Mabayoje VO, Raji AA, et al. Feto - maternal haemorrhage in parturients: Incidence and its determinants. J Obstet Gynaecol 2008; 28:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/45/3800/abstract/11\">",
"      Salim R, Ben-Shlomo I, Nachum Z, et al. The incidence of large fetomaternal hemorrhage and the Kleihauer-Betke test. Obstet Gynecol 2005; 105:1039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/45/3800/abstract/12\">",
"      Giacoia GP. Severe fetomaternal hemorrhage: a review. Obstet Gynecol Surv 1997; 52:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/45/3800/abstract/13\">",
"      Devi B, Jennison RF, Langley FA. Significance of placental pathology in transplacental haemorrhage. J Clin Pathol 1968; 21:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/45/3800/abstract/14\">",
"      Murphy KW, Venkatraman N, Stevens J. Limitations of ultrasound in the diagnosis of fetomaternal haemorrhage. BJOG 2000; 107:1317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/45/3800/abstract/15\">",
"      Glasser L, West JH, Hagood RM. Incompatible fetomaternal transfusion with maternal intravascular lysis. Transfusion 1970; 10:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/45/3800/abstract/16\">",
"      Modanlou HD, Freeman RK, Ortiz O, et al. Sinusoidal fetal heart rate pattern and severe fetal anemia. Obstet Gynecol 1977; 49:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/45/3800/abstract/17\">",
"      Nicolaides KH, Sadovsky G, Visser GH. Heart rate patterns in normoxemic, hypoxemic, and anemic second-trimester fetuses. Am J Obstet Gynecol 1989; 160:1034.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/45/3800/abstract/18\">",
"      Laube DW, Schauberger CW. Fetomaternal bleeding as a cause for \"unexplained\" fetal death. Obstet Gynecol 1982; 60:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/45/3800/abstract/19\">",
"      KLEIHAUER E, BRAUN H, BETKE K. [Demonstration of fetal hemoglobin in erythrocytes of a blood smear]. Klin Wochenschr 1957; 35:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/45/3800/abstract/20\">",
"      Sandler SG, Gottschall JL. Postpartum Rh immunoprophylaxis. Obstet Gynecol 2012; 120:1428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/45/3800/abstract/21\">",
"      Wylie BJ, D'Alton ME. Fetomaternal hemorrhage. Obstet Gynecol 2010; 115:1039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/45/3800/abstract/22\">",
"      Dziegiel MH, Nielsen LK, Berkowicz A. Detecting fetomaternal hemorrhage by flow cytometry. Curr Opin Hematol 2006; 13:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/45/3800/abstract/23\">",
"      Bromilow IM, Duguid JK. Measurement of feto-maternal haemorrhage: a comparative study of three Kleihauer techniques and tow flow cytometry methods. Clin Lab Haematol 1997; 19:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/45/3800/abstract/24\">",
"      ACOG Practice Bulletin No. 102: management of stillbirth. Obstet Gynecol 2009; 113:748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/45/3800/abstract/25\">",
"      Sueters M, Arabin B, Oepkes D. Doppler sonography for predicting fetal anemia caused by massive fetomaternal hemorrhage. Ultrasound Obstet Gynecol 2003; 22:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/45/3800/abstract/26\">",
"      Dhanraj D, Lambers D. The incidences of positive Kleihauer-Betke test in low-risk pregnancies and maternal trauma patients. Am J Obstet Gynecol 2004; 190:1461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/45/3800/abstract/27\">",
"      Muench MV, Baschat AA, Reddy UM, et al. Kleihauer-betke testing is important in all cases of maternal trauma. J Trauma 2004; 57:1094.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/45/3800/abstract/28\">",
"      Chames MC, Pearlman MD. Trauma during pregnancy: outcomes and clinical management. Clin Obstet Gynecol 2008; 51:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/45/3800/abstract/29\">",
"      Goodwin TM, Breen MT. Pregnancy outcome and fetomaternal hemorrhage after noncatastrophic trauma. Am J Obstet Gynecol 1990; 162:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/45/3800/abstract/30\">",
"      Pearlman MD, Tintinallli JE, Lorenz RP. A prospective controlled study of outcome after trauma during pregnancy. Am J Obstet Gynecol 1990; 162:1502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/45/3800/abstract/31\">",
"      Pepperell RJ, Rubinstein E, MacIsaac IA. Motor-car accidents during pregnancy. Med J Aust 1977; 1:203.",
"     </a>",
"    </li>",
"    <li>",
"     Brecher, ME. Technical Manual of the American Association of Blood Banks. American Association of Blood Banks, Bethesda, Maryland 2005.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/45/3800/abstract/33\">",
"      Rubod C, Houfflin V, Belot F, et al. Successful in utero treatment of chronic and massive fetomaternal hemorrhage with fetal hydrops. Fetal Diagn Ther 2006; 21:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/45/3800/abstract/34\">",
"      Zizka Z, Fait T, Belosovicova H, et al. ABO fetomaternal compatibility poses a risk for massive fetomaternal transplacental hemorrhage. Acta Obstet Gynecol Scand 2008; 87:1011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/45/3800/abstract/35\">",
"      Catalano PM, Capeless EL. Fetomaternal bleeding as a cause of recurrent fetal morbidity and mortality. Obstet Gynecol 1990; 76:972.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/45/3800/abstract/36\">",
"      Maass B, W&uuml;rfel B, Fusch C. Recurrent fetomaternal transfusion in two consecutive pregnancies. Prenat Diagn 2001; 21:791.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6806 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-201.211.0.116-70E2D5C64D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_45_3800=[""].join("\n");
var outline_f3_45_3800=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      INCIDENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      LABORATORY EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Kleihauer-Betke",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Flow cytometry",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      INDICATIONS FOR DIAGNOSTIC EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Fetal demise",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Decreased fetal movement",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Sinusoidal FHR or hydrops fetalis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Nonreassuring fetal testing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Indeterminate fetal testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Maternal abdominal trauma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Unexplained neonatal anemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      MANAGEMENT OF SPONTANEOUS FMH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Massive hemorrhage/moderate to severe anemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Small hemorrhage/no or mild anemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5478147\">",
"      Anti-D immune globulin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      RECURRENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/6806\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/6806|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?42/53/43856\" title=\"algorithm 1\">",
"      Algorithm for management of suspected fetomaternal hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/6806|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?2/36/2624\" title=\"picture 1\">",
"      Kleihauer-Betke stain for fetal hemoglobin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/6806|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?12/38/12902\" title=\"waveform 1\">",
"      Sinusoidal FHR pattern",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/37/15959?source=related_link\">",
"      Evaluation of decreased fetal movements",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/59/38839?source=related_link\">",
"      Evaluation of stillbirth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/36/31306?source=related_link\">",
"      Incidence, etiology, and prevention of stillbirth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/57/13210?source=related_link\">",
"      Intrauterine fetal transfusion of red blood cells",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/21/5464?source=related_link\">",
"      Management of pregnancy complicated by Rhesus (Rh) alloimmunization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/37/34393?source=related_link\">",
"      Nonimmune hydrops fetalis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/44/40648?source=related_link\">",
"      Prevention of Rh(D) alloimmunization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/29/23001?source=related_link\">",
"      Structure and function of normal human hemoglobins",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_45_3801="Pharmacologic treatment of obstructive sleep apnea in adults";
var content_f3_45_3801=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pharmacologic treatment of obstructive sleep apnea in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/45/3801/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/45/3801/contributors\">",
"     Charles W Atwood, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/45/3801/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/45/3801/contributors\">",
"     Robert C Basner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/45/3801/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/45/3801/contributors\">",
"     April F Eichler, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?3/45/3801/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 9, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Obstructive sleep apnea (OSA) is characterized by obstructive apneas and hypopneas due to repetitive collapse of the upper airway during sleep. Primary therapy (eg, positive airway pressure, oral appliances, or, occasionally, surgery) is intended to prevent or overcome this upper airway obstruction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/48/2826?source=see_link\">",
"     \"Management of obstructive sleep apnea in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pharmacologic therapy has been evaluated as a potential primary OSA therapy, since it tends to be less burdensome than the current primary therapies. However, no agent has been identified that prevents or overcomes upper airway obstruction enough to justify pharmacologic therapy as a primary therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?3/45/3801/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pharmacologic therapy that promotes wakefulness may be useful for treating excessive daytime sleepiness that persists despite adequate primary therapy. Such therapy is referred to as adjunctive therapy because it is added to the primary therapy and targets residual symptoms rather than the underlying cause of the disorder. In this case, adequate primary therapy is defined as normalization of the apnea hypopnea index (the number of apneas and hypopneas per hour of sleep) and maintenance of acceptable oxyhemoglobin saturation during sleep [",
"    <a class=\"abstract\" href=\"UTD.htm?3/45/3801/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The role of pharmacologic therapy in OSA is discussed here. Primary therapy for OSA (eg, positive airway pressure, oral appliances, or, occasionally, surgery) is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/48/2826?source=see_link\">",
"     \"Management of obstructive sleep apnea in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PHARMACOLOGIC THERAPIES THAT TARGET OSA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Numerous pharmacologic agents have been investigated as potential primary therapies for patients with OSA. However, no agent has been identified that prevents or overcomes upper airway obstruction enough to justify pharmacologic therapy as a primary therapy in the routine management of patients with OSA [",
"    <a class=\"abstract\" href=\"UTD.htm?3/45/3801/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. It is unknown whether pharmacologic agents used concurrently with positive airway pressure therapy lowers the amount of airway pressure required to treat the disorder. Some of the agents that have been studied as potential primary therapies are described in this section.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Acetazolamide",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5752?source=see_link\">",
"     Acetazolamide",
"    </a>",
"    stimulates the ventilatory drive by inducing metabolic acidosis. The limited evidence that exists regarding the effects of acetazolamide in patients with OSA indicates that it improves oxygenation, but has minimal effect on the frequency of obstructive respiratory events during sleep and no definite effects on patient-important outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?3/45/3801/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]. Thus, acetazolamide is not indicated for the treatment of OSA.",
"   </p>",
"   <p>",
"    The effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5752?source=see_link\">",
"     acetazolamide",
"    </a>",
"    on OSA were illustrated by the following trials:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A trial randomly assigned 40 individuals with OSA (baseline obstructive apnea hypopnea index of 49 events per hour) to receive placebo or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5752?source=see_link\">",
"       acetazolamide",
"      </a>",
"      (250 mg twice daily) for three nights, initially at an altitude of 490 meters (baseline) and then at an altitude of 1860 or 2590 meters [",
"      <a class=\"abstract\" href=\"UTD.htm?3/45/3801/abstract/6\">",
"       6",
"      </a>",
"      ]. Following a two week washout period during which they received their normally prescribed continuous positive airway pressure (CPAP) at baseline altitude, each subject crossed over to the other condition and repeated the three nights at an altitude of 490 meters (baseline) and then 1860 or 2590 meters. Use of acetazolamide led to better oxyhemoglobin saturation compared to placebo (88 versus 85 percent at 2590 m, 91 versus 89 percent at 1860 m); however, there was minimal change in the obstructive apnea hypopnea index and the OSA remained severe in all groups (52 versus 55 events per hour at 2590 m, 39 versus 42 events per hour at 1890 m). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/59/15286?source=see_link&amp;anchor=H12#H12\">",
"       \"Sleep related breathing disorders in adults: Definitions\", section on 'Apnea hypopnea index'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Another trial randomly assigned 10 patients with OSA to receive",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5752?source=see_link\">",
"       acetazolamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/5/10327?source=see_link\">",
"       protriptyline",
"      </a>",
"      , or placebo for two weeks [",
"      <a class=\"abstract\" href=\"UTD.htm?3/45/3801/abstract/4\">",
"       4",
"      </a>",
"      ]. Acetazolamide reduced the apnea hypopnea index (26 versus 50 events per hour) and desaturation index (19 versus 29 events per hour) compared to placebo, but there was no symptomatic improvement. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/59/15286?source=see_link&amp;anchor=H12#H12\">",
"       \"Sleep related breathing disorders in adults: Definitions\", section on 'Apnea hypopnea index'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/59/15286?source=see_link&amp;anchor=H14#H14\">",
"       \"Sleep related breathing disorders in adults: Definitions\", section on 'Desaturation'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Donepezil",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/30/10726?source=see_link\">",
"     Donepezil",
"    </a>",
"    is a cholinesterase inhibitor that may improve OSA. This was illustrated by a trial that randomly assigned 23 patients with mild to moderate Alzheimer disease and OSA (defined as an apnea hypopnea index of &gt;5 events per hour) to receive donepezil (5 mg daily) or placebo for three months [",
"    <a class=\"abstract\" href=\"UTD.htm?3/45/3801/abstract/7\">",
"     7",
"    </a>",
"    ]. Donepezil significantly decreased the frequency of obstructive apneas and hypopneas (from 19 to 9 events per hour of sleep) and the duration with an oxyhemoglobin saturation below 90 percent (from 13.5 to 4 percent of the total sleep time). It also blunted the severity of oxyhemoglobin desaturation and improved cognitive performance. Similar findings were reported in a randomized trial of patients with OSA who did not have Alzheimer disease [",
"    <a class=\"abstract\" href=\"UTD.htm?3/45/3801/abstract/8\">",
"     8",
"    </a>",
"    ]. These data require confirmation with larger controlled clinical trials that measure patient-important outcomes before donepezil can be recommended for patients with OSA. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/59/15286?source=see_link&amp;anchor=H12#H12\">",
"     \"Sleep related breathing disorders in adults: Definitions\", section on 'Apnea hypopnea index'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Theophylline",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"     Theophylline",
"    </a>",
"    increases ventilatory drive, likely through its inhibition of adenosine. It has been used to treat patients with periodic breathing or central sleep apnea due to left ventricular systolic dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?3/45/3801/abstract/9\">",
"     9",
"    </a>",
"    ]. In patients with OSA, however, theophylline further disrupts sleep and only minimally reduces (ie, does not normalize) the frequency of obstructive events [",
"    <a class=\"abstract\" href=\"UTD.htm?3/45/3801/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. These effects, combined with the risk of toxicity, indicate that theophylline therapy is not warranted for the management of OSA [",
"    <a class=\"abstract\" href=\"UTD.htm?3/45/3801/abstract/1,12\">",
"     1,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"     theophylline",
"    </a>",
"    on OSA were illustrated by the following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a double-blind crossover trial, 12 patients with OSA were randomly assigned to receive",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"       theophylline",
"      </a>",
"      (800 mg) or placebo nightly for four weeks [",
"      <a class=\"abstract\" href=\"UTD.htm?3/45/3801/abstract/11\">",
"       11",
"      </a>",
"      ]. Theophylline worsened sleep quality and mildly decreased the AHI compared to placebo (40 versus 49 events per hour of sleep).",
"     </li>",
"     <li>",
"      An observational study compared the effectiveness of long-acting",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"       theophylline",
"      </a>",
"      (400 mg) to CPAP therapy in 13 patients with moderate OSA [",
"      <a class=\"abstract\" href=\"UTD.htm?3/45/3801/abstract/10\">",
"       10",
"      </a>",
"      ]. Theophylline was associated with decreased total sleep time, sleep efficiency, AHI, and desaturation index compared to baseline. CPAP normalized all respiratory and sleep variables.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Progestational agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Progestational agents are respiratory stimulants whose effect on patients with OSA is uncertain. Some studies have reported a net beneficial effect [",
"    <a class=\"abstract\" href=\"UTD.htm?3/45/3801/abstract/13,14\">",
"     13,14",
"    </a>",
"    ], while others have not [",
"    <a class=\"abstract\" href=\"UTD.htm?3/45/3801/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. All of the studies were small, used different formulations, studied different populations, and had important methodological limitations. Thus, more definitive understanding of the effect of progestational therapy on patients with OSA awaits further investigation using more rigorous study designs. Given the risks of hormonal therapy (eg, breast cancer, venous thromboembolic disease, and coronary artery disease [",
"    <a class=\"abstract\" href=\"UTD.htm?3/45/3801/abstract/17\">",
"     17",
"    </a>",
"    ]) and the absence of consistent clinical benefit, the use of progestational agents to treat OSA is not warranted [",
"    <a class=\"abstract\" href=\"UTD.htm?3/45/3801/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/23/32122?source=see_link\">",
"     \"Postmenopausal hormone therapy: Benefits and risks\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Opioid antagonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;Opiate antagonists are short-acting agents that may improve oxygenation in patients with OSA, presumably by stimulating the central nervous system to increase ventilation. However, they also cause significant sleep disruption. In light of the increased sleep disruption (ie, decreased REM sleep) and the practical difficulties associated with administering short-acting agents (ie, frequent dosing), opiate antagonists are not indicated for the management of patients with OSA, despite the improvement of oxyhemoglobin desaturation.",
"   </p>",
"   <p>",
"    The effects of opiate antagonists on OSA were demonstrated by a trial that compared the effect of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/24/35207?source=see_link\">",
"     naloxone",
"    </a>",
"    to saline in 10 patients with OSA [",
"    <a class=\"abstract\" href=\"UTD.htm?3/45/3801/abstract/18\">",
"     18",
"    </a>",
"    ]. Naloxone decreased the oxyhemoglobin desaturation index and the severity of oxyhemoglobin desaturation episodes, but the amount of rapid eye movement (REM) sleep decreased approximately 80 percent. It is likely that the improved nocturnal oxygenation was a consequence of less REM-related skeletal muscle atonia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Nicotine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Similar to opiate antagonists, nicotine stimulates the central nervous system to increase ventilation and may improve oxygenation in patients with OSA. However, it can also cause significant sleep disruption [",
"    <a class=\"abstract\" href=\"UTD.htm?3/45/3801/abstract/19-21\">",
"     19-21",
"    </a>",
"    ], as well as addiction and numerous other side effects. Due to its uncertain efficacy and adverse effects, nicotine is not recommended for the treatment of OSA.",
"   </p>",
"   <p>",
"    The effects of nicotine on OSA were illustrated by a trial that compared transdermal nicotine to a control in eight patients with OSA [",
"    <a class=\"abstract\" href=\"UTD.htm?3/45/3801/abstract/21\">",
"     21",
"    </a>",
"    ]. Nicotine improved the mean oxyhemoglobin saturation, but did not alter the minimum oxyhemoglobin saturation, the frequency of apneas or hypopneas, or the duration of apneas or hypopneas.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Thyroxine",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of OSA in patients with hypothyroidism may be greater than 25 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?3/45/3801/abstract/22-24\">",
"     22-24",
"    </a>",
"    ]. Conversely, the prevalence of hypothyroidism in patients with OSA is less than 3 percent. Thyroxine therapy in patients with coexisting hypothyroidism and OSA has eliminated the OSA in some studies, even in the absence of weight loss [",
"    <a class=\"abstract\" href=\"UTD.htm?3/45/3801/abstract/16,24,25\">",
"     16,24,25",
"    </a>",
"    ]. The resolution of macroglossia may play a role. Patients with OSA who have hypothyroidism should be treated with replacement therapy. There is no role for thyroid replacement in euthyroid patients with OSA.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Serotonergic agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with OSA may have a central deficiency of serotonin activity, which may be partially explained by obesity and insulin resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?3/45/3801/abstract/26\">",
"     26",
"    </a>",
"    ]. This deficiency may contribute to OSA because serotonin plays a role in hypoglossal nerve function. In theory, increasing serotonin may increase genioglossal tone and improve OSA. This is the rationale for testing serotonin reuptake inhibitors and selective serotonin receptor antagonists as potential therapies for OSA. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/28/5578?source=see_link\">",
"     \"Serotonin-norepinephrine reuptake inhibitors (SNRIs): Pharmacology, administration, and side effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    All of the studies reported so far have been small with few events; therefore, the estimated effects have been imprecise. The best results were achieved using a combination of the selective serotonin receptor antagonist, odansetron, and the serotonin reuptake inhibitor,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15130?source=see_link\">",
"     fluoxetine",
"    </a>",
"    . The trial randomly assigned 35 patients with OSA (defined as an apnea hypopnea index of &gt;10 events per hour) to receive placebo, odansetron (24 mg) alone, odansetron (24 mg) plus fluoxetine (5 mg), or odansetron (24 mg) plus fluoxetine (10 mg) for 28 days [",
"    <a class=\"abstract\" href=\"UTD.htm?3/45/3801/abstract/27\">",
"     27",
"    </a>",
"    ]. Only the combinations of odansetron and fluoxetine reduced the apnea hypopnea index, with the combination of odansetron (24 mg) plus fluoxetine (10 mg) having a larger magnitude of effect than the combination of odansetron (24 mg) plus fluoxetine (5 mg). The combination of odansetron (24 mg) plus fluoxetine (10 mg) also induced a trend toward better oxyhemoglobin saturation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/59/15286?source=see_link&amp;anchor=H12#H12\">",
"     \"Sleep related breathing disorders in adults: Definitions\", section on 'Apnea hypopnea index'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/50/15146?source=see_link\">",
"     paroxetine",
"    </a>",
"    alone has been studied:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A double-blind crossover trial randomly assigned 20 patients with OSA to receive",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/50/15146?source=see_link\">",
"       paroxetine",
"      </a>",
"      or placebo daily for six weeks [",
"      <a class=\"abstract\" href=\"UTD.htm?3/45/3801/abstract/28\">",
"       28",
"      </a>",
"      ]. Paroxetine mildly decreased, but did not normalize, the apnea index during non-REM (NREM) sleep only (30 versus 36 events per hour). There were no effects on sleepiness, memory, mood, or indices of respiratory events.",
"     </li>",
"     <li>",
"      Another double-blind crossover trial randomly assigned eight patients with OSA and an apnea hypopnea index greater than 60 events per hour to receive",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/50/15146?source=see_link\">",
"       paroxetine",
"      </a>",
"      or placebo, then measured genioglossus muscle electrical activity [",
"      <a class=\"abstract\" href=\"UTD.htm?3/45/3801/abstract/29\">",
"       29",
"      </a>",
"      ]. Paroxetine increased genioglossus inspiratory activity, but did not alter the duration or number of events.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Larger controlled clinical trials are necessary before treatment of OSA with serotonin reuptake inhibitors is warranted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Protriptyline",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/5/10327?source=see_link\">",
"     Protriptyline",
"    </a>",
"    is a tricyclic antidepressant that potently suppresses REM sleep. In theory, decreasing REM sleep may decrease the frequency or severity of obstructive events because OSA is often most severe during this stage of sleep. However, protriptyline is not recommended for treatment of OSA because its efficacy is unproven and it is associated with significant anticholinergic side effects, including dry mouth, constipation, and urinary retention [",
"    <a class=\"abstract\" href=\"UTD.htm?3/45/3801/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/5/10327?source=see_link\">",
"     protriptyline",
"    </a>",
"    are illustrated by two trials:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A double-blind crossover trial compared the effect of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/5/10327?source=see_link\">",
"       protriptyline",
"      </a>",
"      to placebo in five patients with OSA [",
"      <a class=\"abstract\" href=\"UTD.htm?3/45/3801/abstract/30\">",
"       30",
"      </a>",
"      ]. Protriptyline reduced REM sleep time and subjective daytime sleepiness. Three patients had a statistically significant, but probably not a clinically significant, reduction in their apnea hypopnea index after six months of protriptyline therapy (56 versus 71 events per hour). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/59/15286?source=see_link&amp;anchor=H12#H12\">",
"       \"Sleep related breathing disorders in adults: Definitions\", section on 'Apnea hypopnea index'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A controlled trial randomly assigned 10 patients with OSA to receive",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/5/10327?source=see_link\">",
"       protriptyline",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5752?source=see_link\">",
"       acetazolamide",
"      </a>",
"      , or placebo for two weeks [",
"      <a class=\"abstract\" href=\"UTD.htm?3/45/3801/abstract/4\">",
"       4",
"      </a>",
"      ]. Protriptyline did not have a significant effect on symptoms or the frequency of apneas, hypopneas, arousals, or desaturations, compared to placebo.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Antihypertensives",
"    </span>",
"    &nbsp;&mdash;&nbsp;In theory, antihypertensive agents may impact OSA by affecting afferent baroreceptor activity and autonomic input to ventilatory control centers. However, while antihypertensive agents are appropriate for the treatment of hypertension in patients with OSA, they are not recommended as a therapy for OSA because their effects on OSA are uncertain and they have potential risks.",
"   </p>",
"   <p>",
"    The uncertainty about the effects of antihypertensive agents in OSA is due, in large part, to inconsistent results across studies. Several small studies found that neither",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/7/39031?source=see_link\">",
"     cilazapril",
"    </a>",
"    (an ACE inhibitor) nor celiprolol (a beta-receptor antagonist) reduced OSA severity [",
"    <a class=\"abstract\" href=\"UTD.htm?3/45/3801/abstract/31,32\">",
"     31,32",
"    </a>",
"    ], whereas a large double-blind, randomized trial comparing",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39417?source=see_link\">",
"     metoprolol",
"    </a>",
"    to cilazapril found that both drugs decreased the apnea hypopnea index by nearly 50 percent without altering the sleep pattern [",
"    <a class=\"abstract\" href=\"UTD.htm?3/45/3801/abstract/33\">",
"     33",
"    </a>",
"    ]. Metoprolol decreased the apnea hypopnea index from 40 to 26 events per hour, while cilazapril decreased the apnea hypopnea index from 40 to 27 events per hour. The conflicting data may be due to several factors:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most of the studies evaluated heterogeneous populations of patients with OSA, which may mask the effect of antihypertensives on OSA in subgroups.",
"     </li>",
"     <li>",
"      Most of the studies used different antihypertensive agents, which may variably affect OSA. As an example,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"       propranolol",
"      </a>",
"      may worsen OSA, while",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39417?source=see_link\">",
"       metoprolol",
"      </a>",
"      may have beneficial effects [",
"      <a class=\"abstract\" href=\"UTD.htm?3/45/3801/abstract/33\">",
"       33",
"      </a>",
"      ]. Similarly,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/46/30440?source=see_link\">",
"       atenolol",
"      </a>",
"      reverses the autonomic nervous system dysfunction noted in patients with OSA and hypertension, while",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/56/903?source=see_link\">",
"       isradipine",
"      </a>",
"      (a calcium channel antagonist),",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/4/8263?source=see_link\">",
"       hydrochlorothiazide",
"      </a>",
"      , and spirapril (an ACE inhibitor) do not [",
"      <a class=\"abstract\" href=\"UTD.htm?3/45/3801/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Other drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effects of several additional pharmacologic agents on patients with OSA have been reported. However, the reports are all small. These agents should not be administered as therapy for OSA until larger controlled clinical trials are performed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11295532\">",
"    <span class=\"h3\">",
"     Trazadone",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/0/24584?source=see_link\">",
"     Trazodone",
"    </a>",
"    , an older antidepressant, is widely prescribed for its sleep-inducing side effect, although its effects on OSA have been scarcely studied. It has been hypothesized that trazodone might improve OSA by raising the arousal threshold (a low arousal threshold may predispose individuals to OSA and, therefore, agents that increase the arousal threshold may improve OSA). In one trial of nine patients with OSA (mean apnea hypopnea index of 52 events per hour), trazadone raised the arousal threshold to some stimuli (ie, increasing carbon dioxide tension) but not others (ie, apneas induced by step-wise reduction in CPAP) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/45/3801/abstract/35\">",
"     35",
"    </a>",
"    ]. Thus, further study is necessary to determine the effects of trazodone on the arousal threshold and other aspects of OSA. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/59/15286?source=see_link&amp;anchor=H12#H12\">",
"     \"Sleep related breathing disorders in adults: Definitions\", section on 'Apnea hypopnea index'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Doxapram",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/37/14933?source=see_link\">",
"     Doxapram",
"    </a>",
"    hydrochloride is an intravenous respiratory stimulant. In a small crossover trial, four patients with OSA were administered doxapram or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?3/45/3801/abstract/36\">",
"     36",
"    </a>",
"    ]. Doxapram improved the mean oxyhemoglobin desaturation during apneic and hypopneic episodes, as well as decreasing the mean apnea length. However, the frequency of oxyhemoglobin desaturations was unchanged.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Clonidine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"     Clonidine",
"    </a>",
"    is an alpha-2 adrenergic agonist, with REM suppressant activity. Decreasing REM sleep may decrease the frequency or severity of obstructive events because OSA is often most severe during this stage of sleep. In a crossover trial, eight patients with OSA received clonidine followed by placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?3/45/3801/abstract/37\">",
"     37",
"    </a>",
"    ]. Clonidine suppressed REM sleep with subsequent lack of REM-related apneas in two patients. In four patients, upper airway obstruction resolved during unsuppressed REM sleep.",
"   </p>",
"   <p>",
"    While these beneficial effects may exist in patients with OSA and hypertension who are prescribed",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"     clonidine",
"    </a>",
"    to treat their hypertension, clonidine should not be prescribed as primary therapy for OSA because it can also have adverse effects related to its central nervous system depressant effects. As an example, severe respiratory depression and hypotension were reported in a patient with OSA who was taking clonidine, despite a serum concentration within the therapeutic range [",
"    <a class=\"abstract\" href=\"UTD.htm?3/45/3801/abstract/38\">",
"     38",
"    </a>",
"    ]. This effect was reversed with oral yohimbine, a central sympathetic stimulant.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Baclofen",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/31/36342?source=see_link\">",
"     Baclofen",
"    </a>",
"    is a gamma aminobutyric acid (GABA) agonist and a central nervous system depressant. In a small, double-blind, placebo controlled crossover trial, baclofen increased total sleep time by increasing both NREM and REM sleep [",
"    <a class=\"abstract\" href=\"UTD.htm?3/45/3801/abstract/39\">",
"     39",
"    </a>",
"    ]. Baclofen did not affect the frequency of apneas or hypopneas.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Glutamate antagonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sabeluzole is a glutamate antagonist that decreased the frequency of desaturation during sleep in patients with OSA, but did not appear to affect the abnormal breathing in one trial [",
"    <a class=\"abstract\" href=\"UTD.htm?3/45/3801/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     PHARMACOLOGIC THERAPIES THAT TARGET RESIDUAL SLEEPINESS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients with OSA continue to experience excessive daytime sleepiness despite what is believed to be adequate improvement of the apnea hypopnea index and maintenance of acceptable oxyhemoglobin saturation during sleep due to conventional therapy (positive airway pressure, oral appliances) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/45/3801/abstract/41\">",
"     41",
"    </a>",
"    ]. Pharmacologic therapy may be considered for such patients, after ensuring that they are compliant with therapy, do not have another medical or psychiatric diagnosis (eg, depression) that may account for the continued sleepiness, are not suffering from an undiagnosed coexisting sleep disorder for which disease-specific treatment is available, and have an adequate sleep duration [",
"    <a class=\"abstract\" href=\"UTD.htm?3/45/3801/abstract/1,42,43\">",
"     1,42,43",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/59/15286?source=see_link&amp;anchor=H12#H12\">",
"     \"Sleep related breathing disorders in adults: Definitions\", section on 'Apnea hypopnea index'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Such therapy is referred to as adjunctive therapy because it is added to the primary therapy and targets a residual symptom (excessive daytime sleepiness) rather than the underlying cause of the disorder (recurrent upper airway obstruction). Prior to initiating adjunctive therapy, repeat polysomnography may be performed to ensure that the OSA has been adequately treated.",
"   </p>",
"   <p>",
"    Adjunctive therapy is controversial. Some clinicians believe that excessive daytime sleepiness is frequently independent of OSA and that it is unwise to offer wake-promoting medications to patients with OSA who are sleepy when such therapy is not offered to members of the general community who are similarly sleepy. This view was supported by an observational study that compared the level of subjective sleepiness among 572 patients being treated for OSA to the level of sleepiness among 525 control patients [",
"    <a class=\"abstract\" href=\"UTD.htm?3/45/3801/abstract/44\">",
"     44",
"    </a>",
"    ]. There was no difference in the percentage of patients who had abnormal sleepiness (16 versus 14 percent for the control group). The study measured sleepiness using the Epworth Sleepiness Scale (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?17/29/17874?source=see_link\">",
"     calculator 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/17/35095?source=see_link&amp;anchor=H14#H14\">",
"     \"Quantifying sleepiness\", section on 'Epworth sleepiness scale (ESS)'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The level of daytime sleepiness at which a trial of stimulant therapy may be warranted has not been defined. However, it appears that many clinicians with expertise in the management of sleep disorders base their decision on patient symptoms, rather than a more objective test, such as the Multiple Sleep Latency Test. The Epworth Sleepiness Scale (ESS) score is another measure commonly used to guide decision making about initiating stimulants. Although no single best cut-off value has been determined, we believe that ESS scores of 12 or higher are a reasonable threshold for initiating a discussion with the patient about such a course.",
"   </p>",
"   <p>",
"    If a trial of wakefulness-promoting pharmacologic therapy is selected, several stimulants are available. Only",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/8/1159?source=see_link\">",
"     modafinil",
"    </a>",
"    has been adequately studied in patients who have excessive daytime sleepiness despite adequate treatment of OSA, although most of the studies were funded by the maker of modafinil. This section discusses three stimulants that are commonly used to treat sleepiness: modafinil,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/60/39881?source=see_link\">",
"     methylphenidate",
"    </a>",
"    , and amphetamines.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Modafinil",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/8/1159?source=see_link\">",
"     Modafinil",
"    </a>",
"    acts on the central nervous system, although the mechanism for its effect is unknown. It is first-line adjunctive therapy for the treatment of excessive daytime sleepiness that persists in patients with OSA who have no alternative causes of sleepiness and who have had an adequate response to conventional therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?3/45/3801/abstract/1,42\">",
"     1,42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The effectiveness of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/8/1159?source=see_link\">",
"     modafinil",
"    </a>",
"    has been demonstrated in multiple randomized trials [",
"    <a class=\"abstract\" href=\"UTD.htm?3/45/3801/abstract/45-48\">",
"     45-48",
"    </a>",
"    ]. As an example, a double-blind crossover trial randomly assigned 157 patients with OSA who had persistent daytime sleepiness despite adequate conventional therapy, to receive modafinil (titrated upward from 200 mg to 400 mg) or placebo once daily for 12 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?3/45/3801/abstract/46\">",
"     46",
"    </a>",
"    ]. Excessive daytime sleepiness resolved in a greater proportion of patients in the modafinil group than in the placebo group (51 versus 27 percent), as measured by the Epworth Sleepiness Scale. A subsequent analysis that pooled data from this trial with data from another trial [",
"    <a class=\"abstract\" href=\"UTD.htm?3/45/3801/abstract/46,48\">",
"     46,48",
"    </a>",
"    ], found that modafinil improved productivity, activity, intimacy, and vigilance compared with placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?3/45/3801/abstract/49\">",
"     49",
"    </a>",
"    ]. Both the original trials and the pooled analysis were funded by the maker of modafinil.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/43/31413?source=see_link\">",
"     Armodafinil",
"    </a>",
"    is the R-enantiomer of racemic",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/8/1159?source=see_link\">",
"     modafinil",
"    </a>",
"    . It appears to be similarly effective, according to randomized trials [",
"    <a class=\"abstract\" href=\"UTD.htm?3/45/3801/abstract/50,51\">",
"     50,51",
"    </a>",
"    ]. However, armodafinil and modafinil have never been directly compared.",
"   </p>",
"   <p>",
"    There are conflicting data regarding the impact of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/8/1159?source=see_link\">",
"     modafinil",
"    </a>",
"    therapy on the primary therapy (eg, positive airway pressure therapy). Some studies suggest that reduced daytime sleepiness due to modafinil therapy prompts patients to reduce their use of continuous positive airway pressure (CPAP) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/45/3801/abstract/45,47\">",
"     45,47",
"    </a>",
"    ], while other studies suggest that modafinil doesn't alter CPAP use [",
"    <a class=\"abstract\" href=\"UTD.htm?3/45/3801/abstract/46,48\">",
"     46,48",
"    </a>",
"    ]. In light of the conflicting data, it seems reasonable to closely monitor adherence with conventional therapy in all patients who receive pharmacologic therapy.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/8/1159?source=see_link\">",
"     Modafinil",
"    </a>",
"    given once in the morning typically promotes wakefulness into the early evening without disrupting nighttime sleep. Once it is determined that a trial of modafinil is warranted, it is reasonable to start with 100 mg or 200 mg each morning and then titrate up to 300 or 400 mg as needed. Patients with persistent afternoon sleepiness may benefit from divided dosing with 200 mg in the morning and 200 mg in the early to mid-afternoon. Patients generally report improvement within seven days of starting therapy or increasing a dose.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/8/1159?source=see_link\">",
"     Modafinil",
"    </a>",
"    should be used cautiously in people with a history of arrhythmias or heart disease (eg, angina, recent history of myocardial infarction, left ventricular hypertrophy), although adverse cardiovascular effects (eg, chest pain, hypertension, palpitations) are presumed to be less common with modafinil than alternative stimulants [",
"    <a class=\"abstract\" href=\"UTD.htm?3/45/3801/abstract/52,53\">",
"     52,53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other side effects are uncommon, but include headache, nausea, dry mouth, anorexia, and diarrhea.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/8/1159?source=see_link\">",
"     Modafinil",
"    </a>",
"    addiction has not been reported. Serious and life-threatening rashes, including Stevens-Johnson syndrome and toxic epidermal necrolysis, have been reported. Most cases have occurred within the first 5 weeks of therapy, although rare cases have occurred after long-term use. Rare cases of multiorgan hypersensitivity reactions in association with modafinil use and lone cases of angioedema and anaphylactoid reactions with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/43/31413?source=see_link\">",
"     armodafinil",
"    </a>",
"    have also been reported. Such hypersensitivity reactions typically present with fever and rash associated with organ-system dysfunction. Patients should be advised to discontinue modafinil or armodafinil at the first sign of rash.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Methylphenidate",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/60/39881?source=see_link\">",
"     Methylphenidate",
"    </a>",
"    is also a central nervous system stimulant with an unknown mechanism. Two actions have been proposed: a sympathomimetic effect and stimulation of the brainstem reticular activating system and cortex.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/60/39881?source=see_link\">",
"     Methylphenidate",
"    </a>",
"    is commonly used to treat attention deficit hyperactivity disorder (ADHD), narcolepsy, or mild brain injury. Although clinical trials have not been performed in patients with OSA, some clinicians use methylphenidate as adjunctive therapy to treat daytime sleepiness that has persisted despite adequate conventional therapy.",
"   </p>",
"   <p>",
"    Side effects are uncommon, but include headache, nausea, dry mouth, anorexia, and diarrhea.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/60/39881?source=see_link\">",
"     Methylphenidate",
"    </a>",
"    has sympathomimetic effects and should be used cautiously in patients with a history of arrhythmias or heart disease. Methylphenidate dependency has been reported. The United States Food and Drug Administration (FDA) has directed the makers of all medications approved for the treatment of ADHD, including methylphenidate, to alert patients about the risks of adverse psychiatric symptoms and possible cardiovascular risks [",
"    <a class=\"abstract\" href=\"UTD.htm?3/45/3801/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Amphetamines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Amphetamines are potent central nervous system stimulants and sympathoactive agents. Similar to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/60/39881?source=see_link\">",
"     methylphenidate",
"    </a>",
"    , amphetamines have been used to treat patients with OSA and excessive daytime sleepiness that has persisted despite adequate conventional therapy. Clinical trials evaluating the efficacy of this practice have not been performed.",
"   </p>",
"   <p>",
"    The major toxicities of amphetamines are psychiatric (eg, irritability, psychosis) and cardiovascular (eg, hypertension, heart failure). There are strict regulations governing their prescription because addiction and illicit use has been reported. The United States Food and Drug Administration (FDA) has directed the makers of all medications approved for the treatment of ADHD, including amphetamines, to alert patients about the risks of adverse psychiatric symptoms and possible cardiovascular risks [",
"    <a class=\"abstract\" href=\"UTD.htm?3/45/3801/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Obstructive sleep apnea (OSA) is a disorder characterized by obstructive apneas and hypopneas due to repetitive collapse of the upper airway during sleep. Primary therapy (eg, positive airway pressure, oral appliances, and, occasionally, surgery) prevents or overcomes upper airway obstruction. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pharmacologic agents have been investigated as potential primary therapies for patients with OSA. However, no agent has been identified that prevents or overcomes upper airway obstruction enough to justify pharmacologic therapy as a primary therapy in the routine management of patients with OSA. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pharmacologic therapies that target OSA'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pharmacologic therapy may be a useful to treat excessive daytime sleepiness that persists despite adequate primary therapy. Such therapy is adjunctive because it is added to the primary therapy and targets residual sleepiness rather than the underlying cause of the disorder. Prior to the initiation of adjunctive therapy, compliance with and effectiveness of the primary therapy should be confirmed. Alternative causes of daytime sleepiness should also be excluded. Repeat polysomnography is required to ensure that the OSA has been adequately treated. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Pharmacologic therapies that target residual sleepiness'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with OSA who have persistent daytime sleepiness that is burdensome enough to require therapy, have had alternative causes of daytime sleepiness excluded, and have had the efficacy of their conventional therapy confirmed, we suggest a trial of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/8/1159?source=see_link\">",
"       modafinil",
"      </a>",
"      rather than an alternative stimulant (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). This is based on the recognition that only modafinil has been adequately studied in such patients and that modafinil might have fewer adverse effects than other stimulants. However, modafinil may be the most expensive choice, there is no reason to suspect that its efficacy is superior to the other stimulants, and most of the studies were funded by the makers of modafinil. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Pharmacologic therapies that target residual sleepiness'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The United States Food and Drug Administration has directed the manufacturers of all medications approved for the treatment of attention deficit hyperactivity disorder (including",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/60/39881?source=see_link\">",
"       methylphenidate",
"      </a>",
"      , methamphetamine, and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/44/32454?source=see_link\">",
"       dextroamphetamine",
"      </a>",
"      ) to alert patients about possible cardiovascular risks and risks of adverse psychiatric symptoms associated with the medications. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Methylphenidate'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H22\">",
"       'Amphetamines'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/45/3801/abstract/1\">",
"      Epstein LJ, Kristo D, Strollo PJ Jr, et al. Clinical guideline for the evaluation, management and long-term care of obstructive sleep apnea in adults. J Clin Sleep Med 2009; 5:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/45/3801/abstract/2\">",
"      Hudgel DW, Thanakitcharu S. Pharmacologic treatment of sleep-disordered breathing. Am J Respir Crit Care Med 1998; 158:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/45/3801/abstract/3\">",
"      Randerath WJ, Verbraecken J, Andreas S, et al. Non-CPAP therapies in obstructive sleep apnoea. Eur Respir J 2011; 37:1000.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/45/3801/abstract/4\">",
"      Whyte KF, Gould GA, Airlie MA, et al. Role of protriptyline and acetazolamide in the sleep apnea/hypopnea syndrome. Sleep 1988; 11:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/45/3801/abstract/5\">",
"      Inoue Y, Takata K, Sakamoto I, et al. Clinical efficacy and indication of acetazolamide treatment on sleep apnea syndrome. Psychiatry Clin Neurosci 1999; 53:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/45/3801/abstract/6\">",
"      Nussbaumer-Ochsner Y, Latshang TD, Ulrich S, et al. Patients with obstructive sleep apnea syndrome benefit from acetazolamide during an altitude sojourn: a randomized, placebo-controlled, double-blind trial. Chest 2012; 141:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/45/3801/abstract/7\">",
"      Moraes W, Poyares D, Sukys-Claudino L, et al. Donepezil improves obstructive sleep apnea in Alzheimer disease: a double-blind, placebo-controlled study. Chest 2008; 133:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/45/3801/abstract/8\">",
"      Sukys-Claudino L, Moraes W, Guilleminault C, et al. Beneficial effect of donepezil on obstructive sleep apnea: a double-blind, placebo-controlled clinical trial. Sleep Med 2012; 13:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/45/3801/abstract/9\">",
"      Javaheri S, Parker TJ, Wexler L, et al. Effect of theophylline on sleep-disordered breathing in heart failure. N Engl J Med 1996; 335:562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/45/3801/abstract/10\">",
"      Saletu B, Oberndorfer S, Anderer P, et al. Efficiency of continuous positive airway pressure versus theophylline therapy in sleep apnea: comparative sleep laboratory studies on objective and subjective sleep and awakening quality. Neuropsychobiology 1999; 39:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/45/3801/abstract/11\">",
"      Mulloy E, McNicholas WT. Theophylline in obstructive sleep apnea. A double-blind evaluation. Chest 1992; 101:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/45/3801/abstract/12\">",
"      Espinoza H, Antic R, Thornton AT, McEvoy RD. The effects of aminophylline on sleep and sleep-disordered breathing in patients with obstructive sleep apnea syndrome. Am Rev Respir Dis 1987; 136:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/45/3801/abstract/13\">",
"      Keefe DL, Watson R, Naftolin F. Hormone replacement therapy may alleviate sleep apnea in menopausal women: a pilot study. Menopause 1999; 6:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/45/3801/abstract/14\">",
"      Strohl KP, Hensley MJ, Saunders NA, et al. Progesterone administration and progressive sleep apneas. JAMA 1981; 245:1230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/45/3801/abstract/15\">",
"      Cistulli PA, Barnes DJ, Grunstein RR, Sullivan CE. Effect of short-term hormone replacement in the treatment of obstructive sleep apnoea in postmenopausal women. Thorax 1994; 49:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/45/3801/abstract/16\">",
"      Rajagopal KR, Abbrecht PH, Jabbari B. Effects of medroxyprogesterone acetate in obstructive sleep apnea. Chest 1986; 90:815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/45/3801/abstract/17\">",
"      Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002; 288:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/45/3801/abstract/18\">",
"      Atkinson RL, Suratt PM, Wilhoit SC, Recant L. Naloxone improves sleep apnea in obese humans. Int J Obes 1985; 9:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/45/3801/abstract/19\">",
"      Davila DG, Hurt RD, Offord KP, et al. Acute effects of transdermal nicotine on sleep architecture, snoring, and sleep-disordered breathing in nonsmokers. Am J Respir Crit Care Med 1994; 150:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/45/3801/abstract/20\">",
"      Gothe B, Strohl KP, Levin S, Cherniack NS. Nicotine: a different approach to treatment of obstructive sleep apnea. Chest 1985; 87:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/45/3801/abstract/21\">",
"      Hein H, Kirsten D, Jugert C, Magnussen H. [Nicotine as therapy of obstructive sleep apnea?]. Pneumologie 1995; 49 Suppl 1:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/45/3801/abstract/22\">",
"      Kapur VK, Koepsell TD, deMaine J, et al. Association of hypothyroidism and obstructive sleep apnea. Am J Respir Crit Care Med 1998; 158:1379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/45/3801/abstract/23\">",
"      Lin CC, Tsan KW, Chen PJ. The relationship between sleep apnea syndrome and hypothyroidism. Chest 1992; 102:1663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/45/3801/abstract/24\">",
"      Skjodt NM, Atkar R, Easton PA. Screening for hypothyroidism in sleep apnea. Am J Respir Crit Care Med 1999; 160:732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/45/3801/abstract/25\">",
"      Grunstein RR, Sullivan CE. Sleep apnea and hypothyroidism: mechanisms and management. Am J Med 1988; 85:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/45/3801/abstract/26\">",
"      Hudgel DW, Gordon EA, Meltzer HY. Abnormal serotonergic stimulation of cortisol production in obstructive sleep apnea. Am J Respir Crit Care Med 1995; 152:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/45/3801/abstract/27\">",
"      Prasad B, Radulovacki M, Olopade C, et al. Prospective trial of efficacy and safety of ondansetron and fluoxetine in patients with obstructive sleep apnea syndrome. Sleep 2010; 33:982.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/45/3801/abstract/28\">",
"      Kraiczi H, Hedner J, Dahl&ouml;f P, et al. Effect of serotonin uptake inhibition on breathing during sleep and daytime symptoms in obstructive sleep apnea. Sleep 1999; 22:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/45/3801/abstract/29\">",
"      Berry RB, Yamaura EM, Gill K, Reist C. Acute effects of paroxetine on genioglossus activity in obstructive sleep apnea. Sleep 1999; 22:1087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/45/3801/abstract/30\">",
"      Brownell LG, West P, Sweatman P, et al. Protriptyline in obstructive sleep apnea: a double-blind trial. N Engl J Med 1982; 307:1037.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/45/3801/abstract/31\">",
"      Grote L, Heitmann J, K&ouml;hler U, et al. Effect of angiotensin converting enzyme inhibition [Cilazapril] on blood pressure recording in hypertensive obstructive sleep apneic patients. Blood Press 1997; 6:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/45/3801/abstract/32\">",
"      Plan&egrave;s C, Foucher A, Leroy M, et al. Effect of celiprolol treatment in hypertensive patients with sleep apnea. Sleep 1999; 22:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/45/3801/abstract/33\">",
"      Weichler U, Herres-Mayer B, Mayer J, et al. Influence of antihypertensive drug therapy on sleep pattern and sleep apnea activity. Cardiology 1991; 78:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/45/3801/abstract/34\">",
"      Salo TM, Kantola I, Voipio-Pulkki LM, et al. The effect of four different antihypertensive medications on cardiovascular regulation in hypertensive sleep apneic patients--assessment by spectral analysis of heart rate and blood pressure variability. Eur J Clin Pharmacol 1999; 55:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/45/3801/abstract/35\">",
"      Heinzer RC, White DP, Jordan AS, et al. Trazodone increases arousal threshold in obstructive sleep apnoea. Eur Respir J 2008; 31:1308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/45/3801/abstract/36\">",
"      Suratt PM, Wilhoit SC, Brown ED, Findley LJ. Effect of doxapram on obstructive sleep apnea. Bull Eur Physiopathol Respir 1986; 22:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/45/3801/abstract/37\">",
"      Issa FG. Effect of clonidine in obstructive sleep apnea. Am Rev Respir Dis 1992; 145:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/45/3801/abstract/38\">",
"      Roberge RJ, Kimball ET, Rossi J, Warren J. Clonidine and sleep apnea syndrome interaction: antagonism with yohimbine. J Emerg Med 1998; 16:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/45/3801/abstract/39\">",
"      Finnimore AJ, Roebuck M, Sajkov D, McEvoy RD. The effects of the GABA agonist, baclofen, on sleep and breathing. Eur Respir J 1995; 8:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/45/3801/abstract/40\">",
"      Hedner J, Grunstein R, Eriksson B, Ejnell H. A double-blind, randomized trial of sabeluzole--a putative glutamate antagonist--in obstructive sleep apnea. Sleep 1996; 19:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/45/3801/abstract/41\">",
"      P&eacute;pin JL, Viot-Blanc V, Escourrou P, et al. Prevalence of residual excessive sleepiness in CPAP-treated sleep apnoea patients: the French multicentre study. Eur Respir J 2009; 33:1062.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/45/3801/abstract/42\">",
"      Morgenthaler TI, Kapen S, Lee-Chiong T, et al. Practice parameters for the medical therapy of obstructive sleep apnea. Sleep 2006; 29:1031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/45/3801/abstract/43\">",
"      Veasey SC, Guilleminault C, Strohl KP, et al. Medical therapy for obstructive sleep apnea: a review by the Medical Therapy for Obstructive Sleep Apnea Task Force of the Standards of Practice Committee of the American Academy of Sleep Medicine. Sleep 2006; 29:1036.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/45/3801/abstract/44\">",
"      Stradling JR, Smith D, Crosby J. Post-CPAP sleepiness--a specific syndrome? J Sleep Res 2007; 16:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/45/3801/abstract/45\">",
"      Kingshott RN, Vennelle M, Coleman EL, et al. Randomized, double-blind, placebo-controlled crossover trial of modafinil in the treatment of residual excessive daytime sleepiness in the sleep apnea/hypopnea syndrome. Am J Respir Crit Care Med 2001; 163:918.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/45/3801/abstract/46\">",
"      Pack AI, Black JE, Schwartz JR, Matheson JK. Modafinil as adjunct therapy for daytime sleepiness in obstructive sleep apnea. Am J Respir Crit Care Med 2001; 164:1675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/45/3801/abstract/47\">",
"      Schwartz JR, Hirshkowitz M, Erman MK, Schmidt-Nowara W. Modafinil as adjunct therapy for daytime sleepiness in obstructive sleep apnea: a 12-week, open-label study. Chest 2003; 124:2192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/45/3801/abstract/48\">",
"      Black JE, Hirshkowitz M. Modafinil for treatment of residual excessive sleepiness in nasal continuous positive airway pressure-treated obstructive sleep apnea/hypopnea syndrome. Sleep 2005; 28:464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/45/3801/abstract/49\">",
"      Weaver TE, Chasens ER, Arora S. Modafinil improves functional outcomes in patients with residual excessive sleepiness associated with CPAP treatment. J Clin Sleep Med 2009; 5:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/45/3801/abstract/50\">",
"      Roth T, White D, Schmidt-Nowara W, et al. Effects of armodafinil in the treatment of residual excessive sleepiness associated with obstructive sleep apnea/hypopnea syndrome: a 12-week, multicenter, double-blind, randomized, placebo-controlled study in nCPAP-adherent adults. Clin Ther 2006; 28:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/45/3801/abstract/51\">",
"      Hirshkowitz M, Black JE, Wesnes K, et al. Adjunct armodafinil improves wakefulness and memory in obstructive sleep apnea/hypopnea syndrome. Respir Med 2007; 101:616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/45/3801/abstract/52\">",
"      Hou RH, Langley RW, Szabadi E, Bradshaw CM. Comparison of diphenhydramine and modafinil on arousal and autonomic functions in healthy volunteers. J Psychopharmacol 2007; 21:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/45/3801/abstract/53\">",
"      Wong YN, Simcoe D, Hartman LN, et al. A double-blind, placebo-controlled, ascending-dose evaluation of the pharmacokinetics and tolerability of modafinil tablets in healthy male volunteers. J Clin Pharmacol 1999; 39:30.",
"     </a>",
"    </li>",
"    <li>",
"     FDA directs ADHD drug manufacturers to notify patients about cardiovascular adverse events and psychiatric adverse events file://www.fda.gov/bbs/topics/NEWS/2007/NEW01568.html (Accessed on March 02, 2007).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7687 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-122.96.59.103-18C17D12B8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_45_3801=[""].join("\n");
var outline_f3_45_3801=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PHARMACOLOGIC THERAPIES THAT TARGET OSA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Acetazolamide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Donepezil",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Theophylline",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Progestational agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Opioid antagonists",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Nicotine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Thyroxine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Serotonergic agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Protriptyline",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Antihypertensives",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Other drugs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11295532\">",
"      - Trazadone",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Doxapram",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Clonidine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Baclofen",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Glutamate antagonists",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      PHARMACOLOGIC THERAPIES THAT TARGET RESIDUAL SLEEPINESS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Modafinil",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Methylphenidate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Amphetamines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?17/29/17874?source=related_link\" title=\"calculator 1\">",
"      Calculator: Epworth Sleepiness Scale (ESS)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/48/2826?source=related_link\">",
"      Management of obstructive sleep apnea in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/23/32122?source=related_link\">",
"      Postmenopausal hormone therapy: Benefits and risks",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/17/35095?source=related_link\">",
"      Quantifying sleepiness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/28/5578?source=related_link\">",
"      Serotonin-norepinephrine reuptake inhibitors (SNRIs): Pharmacology, administration, and side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/59/15286?source=related_link\">",
"      Sleep related breathing disorders in adults: Definitions",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_45_3802="Porokeratosis of Mibelli";
var content_f3_45_3802=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F81011%7EDERM%2F62258&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F81011%7EDERM%2F62258&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Porokeratosis of Mibelli",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A large plaque with a slightly atrophic center and a prominent peripheral keratotic ridge is present.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Disseminated superficial actinic porokeratosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Erythematous, well-defined macules with a peripheral rim of scale are present.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_45_3802=[""].join("\n");
var outline_f3_45_3802=null;
var title_f3_45_3803="Antibiotic regimens endometriti";
var content_f3_45_3803=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F64669&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F64669&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Sample antibiotic regimens for endometritis alternatives to the \"Gold Standard\" gentamicin and clindamycin",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Ampicillin-sulbactam 3 grams IV Q 6 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ticarcillin-clavulanate 3.1 grams IV Q 4 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cefoxitin 2 grams IV Q 6 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ceftriaxone 2 grams IV Q 24 hours plus metronidazole 500 mg PO or IV Q 8 hours*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Levofloxacin 500 mg IV Q 24 hours plus metronidazole 500 mg PO or IV Q 8 hours*",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    If chlamydia infection is suspected, azithromycin 1 gram PO for one dose should be added to the regimen.",
"    <div class=\"footnotes\">",
"     * Should not be given to breastfeeding mothers.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_45_3803=[""].join("\n");
var outline_f3_45_3803=null;
var title_f3_45_3804="PUVA treatment schedule by skin type";
var content_f3_45_3804=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F83193&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F83193&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    PUVA treatment schedule by skin type during the clearance phase",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"4\" width=\"25%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Skin type",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"3\">",
"        UVA radiation dose (J/cm",
"        <sup>",
"         2",
"        </sup>",
"        )",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Initial",
"       </td>",
"       <td class=\"subtitle2\">",
"        Increments",
"       </td>",
"       <td class=\"subtitle2\">",
"        Maximum dose",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        I",
"       </td>",
"       <td class=\"centered\">",
"        1.5",
"       </td>",
"       <td class=\"centered\">",
"        0.5",
"       </td>",
"       <td class=\"centered\">",
"        5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        II",
"       </td>",
"       <td class=\"centered\">",
"        2.5",
"       </td>",
"       <td class=\"centered\">",
"        0.5",
"       </td>",
"       <td class=\"centered\">",
"        8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        III",
"       </td>",
"       <td class=\"centered\">",
"        3.5",
"       </td>",
"       <td class=\"centered\">",
"        0.5-1.0",
"       </td>",
"       <td class=\"centered\">",
"        12",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        IV",
"       </td>",
"       <td class=\"centered\">",
"        4.5",
"       </td>",
"       <td class=\"centered\">",
"        1.0",
"       </td>",
"       <td class=\"centered\">",
"        14",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        V",
"       </td>",
"       <td class=\"centered\">",
"        5.5",
"       </td>",
"       <td class=\"centered\">",
"        1.0",
"       </td>",
"       <td class=\"centered\">",
"        16",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        VI",
"       </td>",
"       <td class=\"centered\">",
"        6.5",
"       </td>",
"       <td class=\"centered\">",
"        1.0-1.5",
"       </td>",
"       <td class=\"centered\">",
"        20",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission of: Informa Healthcare, from Phototherapy and Photochemotherapy of Skin Disease, Morison WL, 3rd ed, New York 2005; permission conveyed through Copyright Clearance Center, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_45_3804=[""].join("\n");
var outline_f3_45_3804=null;
var title_f3_45_3805="Early invasive Rx TIMI IIIB";
var content_f3_45_3805=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F81299&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F81299&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Early invasive versus conservative treatment in unstable angina or non-ST elevation myocardial infarction in TIMI IIIB",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Early invasive (n = 740), percent",
"       </td>",
"       <td class=\"subtitle1\">",
"        Early conservative (n = 733), percent",
"       </td>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Death",
"       </td>",
"       <td>",
"        2.4",
"       </td>",
"       <td>",
"        2.5",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nonfatal MI",
"       </td>",
"       <td>",
"        5.1",
"       </td>",
"       <td>",
"        5.7",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Positive six-week ETT",
"       </td>",
"       <td>",
"        8.6",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Total (primary end point)",
"       </td>",
"       <td>",
"        16.2",
"       </td>",
"       <td>",
"        18.1",
"       </td>",
"       <td>",
"        p = 0.33",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Average length of initial hospitalization, days",
"       </td>",
"       <td>",
"        10.2",
"       </td>",
"       <td>",
"        10.9",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Number of patients rehospitalized within&nbsp;six weeks*",
"       </td>",
"       <td>",
"        7.8",
"       </td>",
"       <td>",
"        14.1",
"       </td>",
"       <td>",
"        p &lt;0.001",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"4\">",
"        Number of antianginal medications&bull;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        0",
"       </td>",
"       <td class=\"sublist_other\">",
"        19.3",
"       </td>",
"       <td class=\"sublist_other\">",
"        17",
"       </td>",
"       <td class=\"sublist_other\">",
"        p = 0.02",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        1",
"       </td>",
"       <td class=\"sublist_other\">",
"        37",
"       </td>",
"       <td class=\"sublist_other\">",
"        31",
"       </td>",
"       <td class=\"sublist_other\">",
"        p = 0.02",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        2",
"       </td>",
"       <td class=\"sublist_other\">",
"        25.5",
"       </td>",
"       <td class=\"sublist_other\">",
"        28.3",
"       </td>",
"       <td class=\"sublist_other\">",
"        p = 0.02",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        3",
"       </td>",
"       <td class=\"sublist_other\">",
"        18.3",
"       </td>",
"       <td class=\"sublist_other\">",
"        23.7",
"       </td>",
"       <td class=\"sublist_other\">",
"        p = 0.02",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"4\">",
"        CCSC status at&nbsp;six weeks&bull;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        No angina",
"       </td>",
"       <td class=\"sublist_other\">",
"        76",
"       </td>",
"       <td class=\"sublist_other\">",
"        71.4",
"       </td>",
"       <td class=\"sublist_other\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Class I or II",
"       </td>",
"       <td class=\"sublist_other\">",
"        16.4",
"       </td>",
"       <td class=\"sublist_other\">",
"        19.1",
"       </td>",
"       <td class=\"sublist_other\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Class III or IV",
"       </td>",
"       <td class=\"sublist_other\">",
"        7.6",
"       </td>",
"       <td class=\"sublist_other\">",
"        9.5",
"       </td>",
"       <td class=\"sublist_other\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     MI: myocardial infarction; ETT: exercise tolerance test; CCSC: Canadian Cardiovascular Society classification.",
"    </div>",
"    <div class=\"reference\">",
"     * Based on 707 patients in the early invasive and 711 patients in the early conservative strategies.",
"     <br>",
"      &bull; Based on 701 patients in the early invasive and 706 patients in the early conservative strategies.",
"      <br>",
"       Data from TIMI III Investigators, Circulation 1994; 89:1545.",
"      </br>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_45_3805=[""].join("\n");
var outline_f3_45_3805=null;
var title_f3_45_3806="Contents";
var content_f3_45_3806=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      Specialties",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     <strong>",
"      Specialties",
"     </strong>",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div id=\"tocLinks\">",
"   <h1>",
"    Table of Contents",
"   </h1>",
"   <p>",
"    A subscription to UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    includes access to over 9,500 topics in 21 specialties. Click on a specialty to view the list of topics.",
"   </p>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds valign=\"top\" width=\"33%\">",
"        <a class=\"tocItem\" href=\"UTD.htm?3/13/3294\">",
"         What's New",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?18/22/18798\">",
"         Patient Information",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?0/40/654\">",
"         Authors and Editors",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?10/42/10926\">",
"         Adult and Pediatric Emergency Medicine",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?23/51/24382\">",
"         Adult Primary Care and Internal Medicine",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?43/1/44061\">",
"         Allergy and Immunology",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?0/37/606\">",
"         Calculators",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?5/3/5182\">",
"         Cardiovascular Medicine",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?2/59/3006\">",
"         Dermatology",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?32/20/33101\">",
"         Drug Information",
"        </a>",
"        <br/>",
"       </tds>",
"       <tds valign=\"top\" width=\"33%\">",
"        <a class=\"tocItem\" href=\"UTD.htm?1/56/1934\">",
"         Endocrinology and Diabetes",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?1/34/1568\">",
"         Family Medicine and General Practice",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?3/12/3278\">",
"         Gastroenterology and Hepatology",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?5/48/5902\">",
"         General Surgery",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?43/6/44141\">",
"         Geriatrics",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?39/57/40861\">",
"         Hematology",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?2/63/3070\">",
"         Hospital Medicine",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?15/21/15710\">",
"         Infectious Diseases",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?0/41/670\">",
"         Nephrology and Hypertension",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?0/63/1022\">",
"         Neurology",
"        </a>",
"        <br/>",
"       </tds>",
"       <tds valign=\"top\" width=\"33%\">",
"        <a class=\"tocItem\" href=\"UTD.htm?6/40/6798\">",
"         Obstetrics, Gynecology and Women's Health",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?3/43/3774\">",
"         Oncology",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?34/55/35709\">",
"         Palliative Care",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?17/55/18302\">",
"         Pediatrics",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?5/62/6121\">",
"         Practice Changing UpDates",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?41/24/42381\">",
"         Psychiatry",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?8/24/8590\">",
"         Pulmonary, Critical Care, and Sleep Medicine",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?3/39/3710\">",
"         Rheumatology",
"        </a>",
"        <br/>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-67F58DD1C0-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f3_45_3806=[""].join("\n");
var outline_f3_45_3806=null;
var title_f3_45_3807="A1C pramlin vs Pbo B";
var content_f3_45_3807=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F60521&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F60521&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Mean change &plusmn; standard deviation in A1c and body weight in patients with type 2 diabetes treated with insulin plus either pramlintide or placebo",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 433px; height: 446px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * p&lt;0.05.",
"     <br>",
"      &bull; p&lt;0.001.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Buse, J, Weyer, C, Maggs, D. Amylin replacement with pramlintide in type 1 and type 2 diabetes: A physiological approach to overcome barriers with insulin therapy. Clinical Diabetes 2002; 20:137. Copyright &copy; 2002 The American Diabetes Association.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_45_3807=[""].join("\n");
var outline_f3_45_3807=null;
